<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Lancet Neurol</journal-id><journal-id journal-id-type="iso-abbrev">Lancet Neurol</journal-id><journal-title-group><journal-title>The Lancet. Neurology</journal-title></journal-title-group><issn pub-type="ppub">1474-4422</issn><issn pub-type="epub">1474-4465</issn><publisher><publisher-name>Lancet Pub. Group</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">37596007</article-id><article-id pub-id-type="pmc">PMC11860300</article-id><article-id pub-id-type="pii">S1474-4422(23)00246-6</article-id><article-id pub-id-type="doi">10.1016/S1474-4422(23)00246-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Evaluation of the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-STEPS): an international, multicentre, pilot cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" id="au10"><name><surname>D'Gama</surname><given-names>Alissa M</given-names></name><degrees>PhD</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au20"><name><surname>Mulhern</surname><given-names>Sarah</given-names></name><degrees>MGenCouns</degrees><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au30"><name><surname>Sheidley</surname><given-names>Beth R</given-names></name><degrees>MS</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au40"><name><surname>Boodhoo</surname><given-names>Fadil</given-names></name><degrees>MD</degrees><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au50"><name><surname>Buts</surname><given-names>Sarah</given-names></name><degrees>MD</degrees><xref rid="aff8" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au60"><name><surname>Chandler</surname><given-names>Natalie J</given-names></name><degrees>PhD</degrees><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au70"><name><surname>Cobb</surname><given-names>Joanna</given-names></name><degrees>PhD</degrees><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au80"><name><surname>Curtis</surname><given-names>Meredith</given-names></name><degrees>MHSc</degrees><xref rid="aff10" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="au90"><name><surname>Higginbotham</surname><given-names>Edward J</given-names></name><degrees>MSc</degrees><xref rid="aff10" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="au100"><name><surname>Holland</surname><given-names>Jonathon</given-names></name><degrees>MB BChir</degrees><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au110"><name><surname>Khan</surname><given-names>Tayyaba</given-names></name><degrees>MPH</degrees><xref rid="aff11" ref-type="aff">k</xref></contrib><contrib contrib-type="author" id="au120"><name><surname>Koh</surname><given-names>Julia</given-names></name><degrees>BS</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au130"><name><surname>Liang</surname><given-names>Nicole S Y</given-names></name><degrees>MSc</degrees><xref rid="aff13" ref-type="aff">m</xref><xref rid="aff14" ref-type="aff">n</xref></contrib><contrib contrib-type="author" id="au140"><name><surname>McRae</surname><given-names>Lyndsey</given-names></name><degrees>MN</degrees><xref rid="aff16" ref-type="aff">p</xref></contrib><contrib contrib-type="author" id="au150"><name><surname>Nesbitt</surname><given-names>Sarah E</given-names></name><degrees>PhD</degrees><xref rid="aff9" ref-type="aff">i</xref><xref rid="aff17" ref-type="aff">q</xref></contrib><contrib contrib-type="author" id="au160"><name><surname>Oby</surname><given-names>Brandon T</given-names></name><degrees>BS</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au170"><name><surname>Paternoster</surname><given-names>Ben</given-names></name><degrees>BSc</degrees><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au180"><name><surname>Patton</surname><given-names>Alistair</given-names></name><degrees>MBBCh</degrees><xref rid="aff19" ref-type="aff">s</xref></contrib><contrib contrib-type="author" id="au190"><name><surname>Rose</surname><given-names>Graham</given-names></name><degrees>PhD</degrees><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au200"><name><surname>Scotchman</surname><given-names>Elizabeth</given-names></name><degrees>PhD</degrees><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au210"><name><surname>Valentine</surname><given-names>Rozalia</given-names></name><degrees>MS</degrees><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au220"><name><surname>Wiltrout</surname><given-names>Kimberly N</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><collab>Gene-STEPS Study Group</collab><xref rid="fn1" ref-type="fn">*</xref></contrib><contrib contrib-type="author"><collab>IPCHiP Executive Committee</collab><xref rid="fn1" ref-type="fn">*</xref></contrib><contrib contrib-type="author" id="au230"><name><surname>Hayeems</surname><given-names>Robin Z</given-names></name><degrees>PhD</degrees><xref rid="aff12" ref-type="aff">l</xref><xref rid="aff20" ref-type="aff">t</xref></contrib><contrib contrib-type="author" id="au240"><name><surname>Jain</surname><given-names>Puneet</given-names></name><degrees>DM</degrees><xref rid="aff16" ref-type="aff">p</xref><xref rid="aff21" ref-type="aff">u</xref></contrib><contrib contrib-type="author" id="au250"><name><surname>Lunke</surname><given-names>Sebastian</given-names></name><degrees>PhD</degrees><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff6" ref-type="aff">f</xref><xref rid="aff22" ref-type="aff">v</xref></contrib><contrib contrib-type="author" id="au260"><name><surname>Marshall</surname><given-names>Christian R</given-names></name><degrees>PhD</degrees><xref rid="aff10" ref-type="aff">j</xref><xref rid="aff15" ref-type="aff">o</xref></contrib><contrib contrib-type="author" id="au270"><name><surname>Rockowitz</surname><given-names>Shira</given-names></name><degrees>PhD</degrees><xref rid="aff25" ref-type="aff">y</xref><xref rid="aff26" ref-type="aff">z</xref><xref rid="aff27" ref-type="aff">aa</xref></contrib><contrib contrib-type="author" id="au280"><name><surname>Sebire</surname><given-names>Neil J</given-names></name><degrees>Prof</degrees><degrees>MD</degrees><xref rid="aff28" ref-type="aff">ab</xref></contrib><contrib contrib-type="author" id="au290"><name><surname>Stark</surname><given-names>Zornitza</given-names></name><degrees>Prof</degrees><degrees>DM</degrees><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff23" ref-type="aff">w</xref></contrib><contrib contrib-type="author" id="au300"><name><surname>White</surname><given-names>Susan M</given-names></name><degrees>Prof</degrees><degrees>MBBS</degrees><xref rid="aff5" ref-type="aff">e</xref><xref rid="aff23" ref-type="aff">w</xref></contrib><contrib contrib-type="author" id="au310"><name><surname>Chitty</surname><given-names>Lyn S</given-names></name><degrees>Prof</degrees><degrees>PhD</degrees><xref rid="aff9" ref-type="aff">i</xref><xref rid="aff17" ref-type="aff">q</xref></contrib><contrib contrib-type="author" id="au320"><name><surname>Cross</surname><given-names>J Helen</given-names></name><degrees>Prof</degrees><degrees>PhD</degrees><xref rid="aff7" ref-type="aff">g</xref><xref rid="aff18" ref-type="aff">r</xref></contrib><contrib contrib-type="author" id="au330"><name><surname>Scheffer</surname><given-names>Ingrid E</given-names></name><degrees>Prof</degrees><degrees>PhD</degrees><xref rid="aff6" ref-type="aff">f</xref><xref rid="aff23" ref-type="aff">w</xref><xref rid="aff24" ref-type="aff">x</xref><xref rid="aff29" ref-type="aff">ac</xref><xref rid="aff30" ref-type="aff">ad</xref></contrib><contrib contrib-type="author" id="au340"><name><surname>Chau</surname><given-names>Vann</given-names></name><degrees>MD</degrees><xref rid="aff16" ref-type="aff">p</xref><xref rid="aff21" ref-type="aff">u</xref><xref rid="fn2" ref-type="fn">&#x02020;</xref></contrib><contrib contrib-type="author" id="au350"><name><surname>Costain</surname><given-names>Gregory</given-names></name><degrees>PhD</degrees><xref rid="aff11" ref-type="aff">k</xref><xref rid="aff14" ref-type="aff">n</xref><xref rid="aff21" ref-type="aff">u</xref><xref rid="aff31" ref-type="aff">ae</xref><xref rid="fn2" ref-type="fn">&#x02020;</xref></contrib><contrib contrib-type="author" id="au360"><name><surname>Poduri</surname><given-names>Annapurna</given-names></name><degrees>Prof</degrees><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="fn2" ref-type="fn">&#x02020;</xref></contrib><contrib contrib-type="author" id="au370"><name><surname>Howell</surname><given-names>Katherine B</given-names></name><degrees>PhD</degrees><xref rid="aff6" ref-type="aff">f</xref><xref rid="aff30" ref-type="aff">ad</xref><xref rid="fn2" ref-type="fn">&#x02020;</xref></contrib><contrib contrib-type="author" id="au380"><name><surname>McTague</surname><given-names>Amy</given-names></name><degrees>PhD</degrees><email>a.mctague@ucl.ac.uk</email><xref rid="aff7" ref-type="aff">g</xref><xref rid="aff32" ref-type="aff">af</xref><xref rid="fn2" ref-type="fn">&#x02020;</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><aff id="aff1"><label>a</label>Epilepsy Genetics Program, Division of Epilepsy and Neurophysiology, Department of Neurology, Boston Children's Hospital, Boston, MA, USA</aff><aff id="aff2"><label>b</label>Division of Newborn Medicine, Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA</aff><aff id="aff3"><label>c</label>Department of Pediatrics, Harvard Medical School, Boston, MA, USA</aff><aff id="aff4"><label>d</label>Department of Neurology, Harvard Medical School, Boston, MA, USA</aff><aff id="aff5"><label>e</label>Victorian Clinical Genetics Service, Melbourne, VIC, Australia</aff><aff id="aff6"><label>f</label>Murdoch Children's Research Institute, Melbourne, VIC, Australia</aff><aff id="aff7"><label>g</label>Department of Neurology, Great Ormond Street Hospital, London, UK</aff><aff id="aff8"><label>h</label>Department of Paediatric Neurology, Aachen University Hospital, Germany</aff><aff id="aff9"><label>i</label>North Thames Genomic Laboratory Hub, Great Ormond Street NHS Foundation Trust, London, UK</aff><aff id="aff10"><label>j</label>Division of Genome Diagnostics, Hospital for Sick Children, Toronto, ON, Canada</aff><aff id="aff11"><label>k</label>Program in Genetics and Genome Biology, SickKids Research Institute, Toronto, ON, Canada</aff><aff id="aff12"><label>l</label>Program in Child Health Evaluative Sciences, SickKids Research Institute, Toronto, ON, Canada</aff><aff id="aff13"><label>m</label>Department of Genetic Counselling, Hospital for Sick Children, Toronto, ON, Canada</aff><aff id="aff14"><label>n</label>Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada</aff><aff id="aff15"><label>o</label>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada</aff><aff id="aff16"><label>p</label>Division of Neurology, Department of Paediatrics, Hospital for Sick Children, Toronto, ON, Canada</aff><aff id="aff17"><label>q</label>Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, UK</aff><aff id="aff18"><label>r</label>Developmental Neurosciences, UCL Great Ormond Street Institute of Child Health, London, UK</aff><aff id="aff19"><label>s</label>Department of Paediatrics, Frimley Park Hospital, Frimley Health NHS Foundation Trust, Frimley, UK</aff><aff id="aff20"><label>t</label>Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada</aff><aff id="aff21"><label>u</label>Department of Paediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada</aff><aff id="aff22"><label>v</label>Department of Pathology, University of Melbourne, Melbourne, VIC, Australia</aff><aff id="aff23"><label>w</label>Department of Paediatrics, University of Melbourne, Melbourne, VIC, Australia</aff><aff id="aff24"><label>x</label>Department of Medicine, University of Melbourne, Melbourne, VIC, Australia</aff><aff id="aff25"><label>y</label>The Manton Center for Orphan Disease Research, Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA</aff><aff id="aff26"><label>z</label>Research Computing, Boston Children's Hospital, Boston, MA, USA</aff><aff id="aff27"><label>aa</label>Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA</aff><aff id="aff28"><label>ab</label>DRIVE Centre, Great Ormond Street Hospital for Children, London, UK</aff><aff id="aff29"><label>ac</label>Austin Health, and Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia</aff><aff id="aff30"><label>ad</label>Department of Neurology, Royal Children's Hospital, Melbourne, VIC, Australia</aff><aff id="aff31"><label>ae</label>Division of Clinical and Metabolic Genetics, Department of Paediatrics, Hospital for Sick Children, Toronto, ON, Canada</aff><aff id="aff32"><label>af</label>Developmental Neurosciences, Zayed Centre for Research into Rare Disease in Children, UCL Great Ormond Street Institute of Child Health, London, UK</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Correspondence to: Dr Amy McTague, Developmental Neurosciences, Zayed Centre for Research into Rare Disease in Children, UCL Great Ormond Street Institute of Child Health, London WC1N 1DZ, UK <email>a.mctague@ucl.ac.uk</email></corresp><fn id="fn1"><label>*</label><p id="cenpara130">Members listed at the end of the Article</p></fn><fn id="fn2"><label>&#x02020;</label><p id="cenpara140">Contributed equally</p></fn></author-notes><pub-date pub-type="pmc-release"><day>1</day><month>9</month><year>2023</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.--><pub-date pub-type="ppub"><month>9</month><year>2023</year></pub-date>
<volume>22</volume><issue>9</issue><fpage>812</fpage><lpage>825</lpage><permissions><copyright-statement>&#x000a9; 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><related-article related-article-type="article-reference" id="d36e8" ext-link-type="doi" xlink:href="10.1016/S1474-4422(23)00289-2"/><abstract id="ceab10"><title>Summary</title><sec><title>Background</title><p>Most neonatal and infantile-onset epilepsies have presumed genetic aetiologies, and early genetic diagnoses have the potential to inform clinical management and improve outcomes. We therefore aimed to determine the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in this population.</p></sec><sec><title>Methods</title><p>We conducted an international, multicentre, cohort study (Gene-STEPS), which is a pilot study of the International Precision Child Health Partnership (IPCHiP). IPCHiP is a consortium of four paediatric centres with tertiary-level subspecialty services in Australia, Canada, the UK, and the USA. We recruited infants with new-onset epilepsy or complex febrile seizures from IPCHiP centres, who were younger than 12 months at seizure onset. We excluded infants with simple febrile seizures, acute provoked seizures, known acquired cause, or known genetic cause. Blood samples were collected from probands and available biological parents. Clinical data were collected from medical records, treating clinicians, and parents. Trio genome sequencing was done when both parents were available, and duo or singleton genome sequencing was done when one or neither parent was available. Site-specific protocols were used for DNA extraction and library preparation. Rapid genome sequencing and analysis was done at clinically accredited laboratories, and results were returned to families. We analysed summary statistics for cohort demographic and clinical characteristics and the timing, diagnostic yield, and clinical impact of rapid genome sequencing.</p></sec><sec><title>Findings</title><p>Between Sept 1, 2021, and Aug 31, 2022, we enrolled 100 infants with new-onset epilepsy, of whom 41 (41%) were girls and 59 (59%) were boys. Median age of seizure onset was 128 days (IQR 46&#x02013;192). For 43 (43% [binomial distribution 95% CI 33&#x02013;53]) of 100 infants, we identified genetic diagnoses, with a median time from seizure onset to rapid genome sequencing result of 37 days (IQR 25&#x02013;59). Genetic diagnosis was associated with neonatal seizure onset versus infantile seizure onset (14 [74%] of 19 <italic>vs</italic> 29 [36%] of 81; p=0&#x000b7;0027), referral setting (12 [71%] of 17 for intensive care, 19 [44%] of 43 non-intensive care inpatient, and 12 [30%] of 40 outpatient; p=0&#x000b7;0178), and epilepsy syndrome (13 [87%] of 15 for self-limited epilepsies, 18 [35%] of 51 for developmental and epileptic encephalopathies, 12 [35%] of 34 for other syndromes; p=0&#x000b7;001). Rapid genome sequencing revealed genetic heterogeneity, with 34 unique genes or genomic regions implicated. Genetic diagnoses had immediate clinical utility, informing treatment (24 [56%] of 43), additional evaluation (28 [65%]), prognosis (37 [86%]), and recurrence risk counselling (all cases).</p></sec><sec><title>Interpretation</title><p>Our findings support the feasibility of implementation of rapid genome sequencing in the clinical care of infants with new-onset epilepsy. Longitudinal follow-up is needed to further assess the role of rapid genetic diagnosis in improving clinical, quality-of-life, and economic outcomes.</p></sec><sec><title>Funding</title><p>American Academy of Pediatrics, Boston Children's Hospital Children's Rare Disease Cohorts Initiative, Canadian Institutes of Health Research, Epilepsy Canada, Feiga Bresver Academic Foundation, Great Ormond Street Hospital Charity, Medical Research Council, Murdoch Children's Research Institute, National Institute of Child Health and Human Development, National Institute for Health and Care Research Great Ormond Street Hospital Biomedical Research Centre, One8 Foundation, Ontario Brain Institute, Robinson Family Initiative for Transformational Research, The Royal Children's Hospital Foundation, University of Toronto McLaughlin Centre.</p></sec></abstract></article-meta></front><body><p id="para10">
<boxed-text id="cetextbox10"><caption><title>Research in context</title></caption><p id="para20">
<bold>Evidence before this study</bold>
</p><p id="para30">We searched PubMed using the terms &#x0201c;epilepsy&#x0201d; OR &#x0201c;seizure(s)&#x0201d; AND &#x0201c;rapid&#x0201d; AND &#x0201c;sequencing&#x0201d; for studies published from database inception to Jan 1, 2023, with no language restrictions. We identified case reports of rapid exome or genome sequencing in patients with epilepsy and several studies of rapid exome or genome sequencing in critically ill paediatric cohorts recruited from neonatal and paediatric intensive care units, including some participants with seizures. We also identified a recent systematic review of genetic testing in the epilepsies, which found the highest diagnostic yield for (non-rapid) genome sequencing (48%) followed by exome sequencing (24%). No studies of rapid exome or genome sequencing (ie, with results available within weeks) in epilepsy cohorts exist.</p><p id="para40">
<bold>Added value of this study</bold>
</p><p id="para50">We report an international, multicentre, cohort study of the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in 100 infants with new-onset epilepsy, using trio-based analyses when parental DNA was available. To date, this study is the first to evaluate rapid sequencing in a disease-specific cohort and the first study consisting of patients mostly outside an intensive care setting. First, we show that rapid genome sequencing has high diagnostic yield (43 [43%] of 100 infants) in infantile epilepsy and demonstrate the feasibility of rapid turnaround for participants recruited from intensive care, non-intensive care inpatient, and outpatient settings across multiple health-care systems. Second, we demonstrate marked genetic heterogeneity across our cohort and demonstrate the ability of rapid genome sequencing to identify genetic diagnoses missed by standard-of-care genetic testing. Third, we observed that most parents of infants with newly diagnosed epilepsy are interested in rapid sequencing, and we demonstrate immediate clinical utility of genetic diagnoses for infants and their families in most cases.</p><p id="para60">
<bold>Implications of all the available evidence</bold>
</p><p id="para70">The findings from this study strongly support the implementation of rapid genome sequencing in the clinical evaluation of infants with new-onset epilepsy. These findings also enhance our understanding of underlying genetic mechanisms of epilepsy. Future research will be needed to understand the personal and long-term utility of early genetic diagnosis in infantile epilepsy. This study provides a framework for advancing precision health that can be implemented for other unexplained conditions beyond epilepsy.</p></boxed-text>
</p><sec id="cesec10"><title>Introduction</title><p id="para80">Infantile-onset epilepsies range in severity from self-limited epilepsies to the larger group of developmental and epileptic encephalopathies.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> The incidence of infantile-onset epilepsies is one in 1200. Patients with developmental and epileptic encephalopathies have drug-resistant seizures, severe developmental impairment, and high mortality risk, with important psychosocial implications for families and substantial economic costs for health systems.<xref rid="bib1" ref-type="bibr">1</xref>, <xref rid="bib2" ref-type="bibr">2</xref></p><p id="para90">Infantile-onset epilepsies often have genetic aetiologies (&#x0003e;800 genes implicated).<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Numerous studies, including a systematic review,<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> show high diagnostic yield and cost-effectiveness of gene panels and exome sequencing in early-onset epilepsies, with genetic testing now considered a first-line investigation.<xref rid="bib5" ref-type="bibr">5</xref>, <xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib8" ref-type="bibr">8</xref> Genome sequencing further increases diagnostic yield,<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> but has not been studied in unselected infantile epilepsy cohorts. In rare disease, genome sequencing, especially trio genome sequencing, has demonstrated substantial diagnostic yield.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref></p><p id="para100">For infants with epilepsy, the identification of a precise diagnosis can guide clinical management and inform prognosis regarding seizure control, developmental outcome, and potential comorbidities. A growing number of genetic epilepsies have precision treatment implications, including four common infantile epilepsy genes (<italic>KCNQ2</italic>, <italic>PRRT2</italic>, <italic>SCN1A</italic>, <italic>SLC2A1</italic>).<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref> Although genetic therapies are not currently available for most epilepsies, tailoring of antiseizure medication is often possible.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> Furthermore, genetic diagnoses could inform eligibility for clinical trials or non-antiseizure medication treatment (eg, epilepsy surgery) and enable precise genetic counselling. In a few studies of the effect of non-genome sequencing genetic testing in epilepsy, genetic diagnoses affected management in 36&#x02013;72% of cases.<xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref></p><p id="para110">Although rapid genetic testing and prompt implementation of individualised treatment, where available, will possibly improve outcomes, a major challenge is that testing often takes months to years, with infants having progressive neurological sequelae from uncontrolled seizures or underlying disease.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> Studies done in neonatal intensive care units (NICUs) and paediatric intensive care units (PICUs) demonstrate high diagnostic yield of rapid (ie, weeks) and ultrarapid (ie, days) genome sequencing for a range of conditions, with clinical utility and reduction in health-care costs.<xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref> To date, rapid genome sequencing has been undertaken primarily in ICUs, and the effect of prompt genetic diagnoses in infants with epilepsy has not been established. In this study, we therefore aimed to demonstrate the feasibility of rapid genome sequencing and investigate the diagnostic yield and clinical utility for infants with new-onset epilepsy.</p></sec><sec id="cesec20"><title>Methods</title><sec id="cesec30"><title>Study design and cohort</title><p id="para120">We conducted an international, multicentre, cohort study (Gene-Shortening Time of Evaluation in Paediatric epilepsy Services [STEPS]), which is a pilot study of the International Precision Child Health Partnership (IPCHiP). This partnership is a consortium of four paediatric centres with tertiary-level subspecialty services, created to advance precision child health: Melbourne Children's Campus (MCC; Murdoch Children's Research Institute and The Royal Children's Hospital) in Australia; The Hospital for Sick Children (SickKids) in Canada; University College London Great Ormond Street Institute of Child Health (UCL GOS ICH) in the UK; and Boston Children's Hospital (BCH) in the USA.</p><p id="para130">We recruited infants with new-onset epilepsy or complex febrile seizures from the IPCHiP centres. Potentially eligible infants were identified by the study team and treating clinicians. The study team reviewed medical records and determined eligibility in discussion with treating clinicians. Infants younger than 12 months at seizure onset and recruited within 6 weeks of study site presentation were enrolled into the study with parental consent. We excluded infants with simple febrile seizures, acute provoked seizures, known acquired cause, or known genetic cause (ie, diagnostic genetic test result or clinical findings consistent with a monogenic syndrome, such as tuberous sclerosis complex). Brain MRI was reviewed to confirm lack of acquired aetiology at screening or as soon as available. We did not exclude infants with structural brain malformations without known genetic cause, or infants with a previous non-diagnostic or concurrent in-progress genetic testing, so as not to disrupt site-specific clinical standard of care. We worked with certified interpreters at each site for non-English-speaking families.</p><p id="para140">This study was approved by each site's institutional review boards and human ethics research committees. We obtained written informed consent from parents for research enrolment, clinically accredited rapid genome sequencing, and results return.</p></sec><sec id="cesec40"><title>Clinical data</title><p id="para150">Clinical data were collected from medical records, treating clinicians, and parents. We documented study site, referral setting (outpatient, non-intensive care inpatient, NICU, PICU), sex, parent-reported race, gestational age, family medical history, epilepsy details (age at seizure onset, seizure type, EEG findings), development before seizure onset, developmental plateau or regression following seizure onset, other neurological and non-neurological features, MRI findings, previous and concurrent genetic testing, and, if applicable, age at death. We classified epilepsy syndrome using the International League Against Epilepsy definitions, and we classified an epilepsy syndrome as other when the participant's presentation did not fit diagnostic criteria for one of those definitions.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref></p></sec><sec id="cesec50"><title>Rapid genome sequencing</title><p id="para160">Blood samples were collected from probands and available biological parents. We did trio genome sequencing when both parents were available, and duo or singleton genome sequencing when one or neither parent was available. Site-specific protocols were used for DNA extraction, library preparation, genome sequencing, variant identification, and validation at clinically accredited laboratories (<xref rid="sec1" ref-type="sec">appendix pp 2&#x02013;3</xref>). All sites performed genome-wide analysis for single nucleotide variants, small insertions and deletions, and copy number variants; the laboratory used by BCH was also clinically accredited to report short tandem repeat expansions in <italic>FMR1</italic> and <italic>DMPK</italic>. Variant classification used standardised criteria (American College of Medical Genetics and Genomics<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> or Association for Clinical Genomic Science). Site-specific policies were followed for reporting variants of uncertain significance and secondary or incidental findings (<xref rid="sec1" ref-type="sec">appendix pp 2&#x02013;3</xref>). Infants with pathogenic or likely pathogenic variants in genes consistent with phenotypes and modes of inheritance were considered to have diagnostic rapid genome sequencing. For infants with variants of uncertain significance that were plausibly explanatory (ie, no data ruled out pathogenicity, but insufficient data were present to classify as pathogenic or likely pathogenic variants), we reviewed medical records for clinical features or further investigations to support pathogenicity to deem variants clinically diagnostic.</p></sec><sec id="cesec60"><title>Effect of rapid genome sequencing</title><p id="para170">We documented age at study site presentation, enrolment, blood collection, and rapid genome sequencing result. Short-term clinical utility (ie, to December, 2022) of rapid genome sequencing was assessed through medical records and treating clinicians. We defined clinical utility as actual influence on treatment, potential for precision therapy, additional investigation indicated or avoided, additional prognostic information, influence on goals of care, or influence on genetic counselling (beyond recurrence risk).</p></sec><sec id="cesec70"><title>Statistical analysis</title><p id="para180">We analysed summary statistics for cohort demographic and clinical characteristics and the timing, diagnostic yield, and clinical effect of rapid genome sequencing. We analysed associations of demographic features, clinical features, and timing with diagnostic rapid genome sequencing using a two-tailed &#x003c7;<sup>2</sup> test, Fisher's exact test, Mann-Whitney test, or Kruskal-Wallis test (based on normality assessment using Kolmogorov-Smirnov and Shapiro-Wilk tests) using the program SPSS (version 27.0), with statistical significance set at p&#x0003c;0&#x000b7;05.</p></sec><sec id="cesec80"><title>Role of the funding source</title><p id="para190">The funders of the study had no role in study design, data collection, data analysis, data interpretation, writing of the report, or the decision to submit for publication.</p></sec></sec><sec id="cesec90"><title>Results</title><p id="para200">Between Sept 1, 2021, and Aug 31, 2022, we screened 147 infants with seizures and confirmed 120 (82%) as eligible for enrolment (<xref rid="fig1" ref-type="fig">figure 1</xref>). Parents of 109 (91%) of 120 eligible infants consented; two (2%) infants became ineligible after consent and seven (6%) after rapid genome sequencing commenced (eg, MRI showed evidence of stroke). For the remaining cohort of 100 infants (59 [59%] were boys and 41 [41%] were girls), 34 (34%) were enrolled from BCH and 22 (22%) each from MCC, SickKids, and UCL GOS ICH. As reported by parents, 63 (63%) of 100 infants were White, 18 (18%) were Asian, eight (8%) were of multiple races, six (6%) were Black, three (3%) were Middle Eastern, and two (2%) were reported as other. 60 (60%) of 100 infants were recruited from inpatient settings (13 [13%] NICU, four [4%] PICU, and 43 [43%] non-intensive care inpatient) and 40 (40%) from outpatient settings (<xref rid="sec1" ref-type="sec">appendix pp 5&#x02013;8</xref>).<fig id="fig1"><label>Figure 1</label><caption><p>Study profile</p><p>GS=genome sequencing. *Not via this study.</p></caption><graphic xlink:href="gr1"/></fig></p><p id="para210">Median age at seizure onset was 128 days (IQR 46&#x02013;192), with neonatal seizure onset (&#x0003c;44 weeks postmenstrual age) occurring in 19 (19%) of 100 infants (<xref rid="tbl1" ref-type="table">table 1</xref>). Focal seizures were the initial seizure type in 50 (50%) of 100 infants. 51 (51%) of 100 infants had developmental and epileptic encephalopathies&#x02014;the most common was infantile epileptic spasms syndrome (32 [32%] of 100) followed by early infantile developmental and epileptic encephalopathy (13 [13%])&#x02014;15 (15%) had self-limited epilepsies, and 34 (34%) had other syndromes.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> MRI revealed malformations of cortical development in 11 (11%) of 100 infants. Of the 81 infants with infantile-onset seizures (between 44 weeks postmenstrual age and 12 months), 20 (25%) had developmental delay before seizure onset and 25 (31%) had developmental plateau or regression following seizure onset (<xref rid="sec1" ref-type="sec">appendix pp 9&#x02013;13</xref>).<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Participant demographics and clinical presentation</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th/><th align="left"><bold>Total (n=100)</bold></th><th align="left"><bold>Genetic diagnosis (n=43)</bold></th><th align="left"><bold>No genetic diagnosis (n=57)</bold></th><th align="left"><bold>p value</bold><xref rid="tbl1fn1" ref-type="table-fn">*</xref></th></tr></thead><tbody><tr><td colspan="2" align="left">Sex</td><td align="left">..</td><td align="left">..</td><td align="left">..</td><td align="left">0&#x000b7;57</td></tr><tr><td/><td align="left">Male</td><td align="left">59 (59%)</td><td align="left">24/59 (41%)</td><td align="left">35/59 (59%)</td><td align="left">..</td></tr><tr><td/><td align="left">Female</td><td align="left">41 (41%)</td><td align="left">19/41 (46%)</td><td align="left">22/41 (54%)</td><td align="left">..</td></tr><tr><td colspan="2" align="left">Prematurity (&#x0003c;37 weeks gestational age)</td><td align="left">15 (15%)</td><td align="left">6/15 (40%)</td><td align="left">9/15 (60%)</td><td align="left">0&#x000b7;80</td></tr><tr><td colspan="2" align="left">Age at seizure onset (days)</td><td align="left">128 (46&#x02013;192)</td><td align="left">105 (17&#x02013;151)</td><td align="left">153 (78&#x02013;200)</td><td align="left">0&#x000b7;0163</td></tr><tr><td colspan="2" align="left">Neonatal seizure onset (&#x0003c;44 weeks postmenstrual age)</td><td align="left">19 (19%)</td><td align="left">14/19 (74%)</td><td align="left">5/19 (26%)</td><td align="left">0&#x000b7;0027</td></tr><tr><td colspan="2" align="left">Seizure onset to site presentation (days)</td><td align="left">7 (1&#x02013;24)</td><td align="left">2 (0&#x02013;15)</td><td align="left">13 (3&#x02013;27)</td><td align="left">0&#x000b7;0164</td></tr><tr><td colspan="2" align="left">Referral setting</td><td align="left">..</td><td align="left">..</td><td align="left">..</td><td align="left">0&#x000b7;0178<xref rid="tbl1fn2" ref-type="table-fn">&#x02020;</xref></td></tr><tr><td/><td align="left">Intensive care</td><td align="left">17 (17%)</td><td align="left">12/17 (71%)</td><td align="left">5/17 (29%)</td><td align="left">..</td></tr><tr><td/><td align="left">Non-intensive care inpatient</td><td align="left">43 (43%)</td><td align="left">19/43 (44%)</td><td align="left">24/43 (56%)</td><td align="left">..</td></tr><tr><td/><td align="left">Outpatient</td><td align="left">40 (40%)</td><td align="left">12/40 (30%)</td><td align="left">28/40 (70%)</td><td align="left">..</td></tr><tr><td colspan="2" align="left">Deceased in first year of life</td><td align="left">6 (6%)</td><td align="left">4/6 (67%)</td><td align="left">2/6 (33%)</td><td align="left">0&#x000b7;40</td></tr><tr><td colspan="2" align="left">Seizure type at onset</td><td align="left">..</td><td align="left">..</td><td align="left">..</td><td align="left">0&#x000b7;29<xref rid="tbl1fn3" ref-type="table-fn">&#x02021;</xref></td></tr><tr><td/><td align="left">Focal</td><td align="left">50 (50%)</td><td align="left">25/50 (50%)</td><td align="left">25/50 (50%)</td><td align="left">..</td></tr><tr><td/><td align="left">Generalised</td><td align="left">35 (35%)</td><td align="left">12/35 (34%)</td><td align="left">23/35 (66%)</td><td align="left">..</td></tr><tr><td/><td align="left">Both</td><td align="left">7 (7%)</td><td align="left">4/7 (57%)</td><td align="left">3/7 (43%)</td><td align="left">..</td></tr><tr><td/><td align="left">Unknown</td><td align="left">8 (8%)</td><td align="left">2/8 (25%)</td><td align="left">6/8 (75%)</td><td align="left">..</td></tr><tr><td colspan="2" align="left">Epilepsy syndrome at onset</td><td align="left">..</td><td align="left">..</td><td align="left">..</td><td align="left">0&#x000b7;001<xref rid="tbl1fn4" ref-type="table-fn">&#x000a7;</xref></td></tr><tr><td colspan="2" align="left">Self-limited epilepsies</td><td align="left">15 (15%)</td><td align="left">13/15 (87%)</td><td align="left">2/15 (13%)</td><td align="left">..</td></tr><tr><td/><td align="left">Self-limited neonatal epilepsy</td><td align="left">3/15 (20%)</td><td align="left">3/3 (100%)</td><td align="left">0</td><td align="left">..</td></tr><tr><td/><td align="left">Self-limited infantile epilepsy</td><td align="left">11/15 (73%)</td><td align="left">9/11 (82%)</td><td align="left">2/11 (18%)</td><td align="left">..</td></tr><tr><td/><td align="left">Self-limited familial neonatal-infantile epilepsy</td><td align="left">1/15 (7%)</td><td align="left">1/1 (100%)</td><td align="left">0</td><td align="left">..</td></tr><tr><td colspan="2" align="left">DEEs</td><td align="left">51 (51%)</td><td align="left">18/51 (35%)</td><td align="left">33/51 (65%)</td><td align="left">..</td></tr><tr><td/><td align="left">Early infantile DEE</td><td align="left">13/51 (25%)</td><td align="left">7/13 (54%)</td><td align="left">6/13 (46%)</td><td align="left">..</td></tr><tr><td/><td align="left">Infantile epileptic spasms syndrome</td><td align="left">32/51 (63%)</td><td align="left">6/32 (19%)</td><td align="left">26/32 (81%)</td><td align="left">..</td></tr><tr><td/><td align="left">Dravet syndrome</td><td align="left">2/51 (4%)</td><td align="left">2/2 (100%)</td><td align="left">0</td><td align="left">..</td></tr><tr><td/><td align="left">Other DEEs</td><td align="left">4/51 (8%)</td><td align="left">3/4 (75%)</td><td align="left">1/4 (25%)</td><td align="left">..</td></tr><tr><td colspan="2" align="left">Other</td><td align="left">34 (34%)</td><td align="left">12/34 (35%)</td><td align="left">22/34 (65%)</td><td align="left">..</td></tr><tr><td/><td align="left">Other focal epilepsy</td><td align="left">24/34 (71%)</td><td align="left">7/24 (29%)</td><td align="left">17/24 (71%)</td><td align="left">..</td></tr><tr><td/><td align="left">Complex febrile seizures</td><td align="left">3/34 (9%)</td><td align="left">1/3 (33%)</td><td align="left">2/3 (67%)</td><td align="left">..</td></tr><tr><td/><td align="left">Other syndrome</td><td align="left">7/34 (21%)</td><td align="left">4/7 (57%)</td><td align="left">3/7 (43%)</td><td align="left">..</td></tr><tr><td colspan="6" align="left">Other clinical features at onset</td></tr><tr><td/><td align="left">Developmental delay before onset for infantile-onset cases</td><td align="left">20/81 (25%)</td><td align="left">11/20 (55%)</td><td align="left">9/20 (45%)</td><td align="left">0&#x000b7;0391</td></tr><tr><td/><td align="left">Developmental regression following onset for infantile-onset cases</td><td align="left">25/81 (31%)</td><td align="left">9/25 (36%)</td><td align="left">16/25 (64%)</td><td align="left">0&#x000b7;98</td></tr><tr><td/><td align="left">Malformation of cortical development</td><td align="left">11 (11%)</td><td align="left">6/11 (55%)</td><td align="left">5/11 (45%)</td><td align="left">0&#x000b7;52</td></tr><tr><td/><td align="left">Abnormal tone (hypotonia, hypertonia, or dystonia)</td><td align="left">27 (27%)</td><td align="left">15/27 (56%)</td><td align="left">12/27 (44%)</td><td align="left">0&#x000b7;12</td></tr><tr><td/><td align="left">Abnormal head size (macrocephaly or microcephaly)</td><td align="left">8 (8%)</td><td align="left">7/8 (88%)</td><td align="left">1/8 (12%)</td><td align="left">0&#x000b7;0195</td></tr><tr><td/><td align="left">Dysmorphic features</td><td align="left">8 (8%)</td><td align="left">5/8 (63%)</td><td align="left">3/8 (37%)</td><td align="left">0&#x000b7;28</td></tr><tr><td/><td align="left">Family history of seizures (first-degree or second-degree relative)</td><td align="left">29 (29%)</td><td align="left">12/29 (41%)</td><td align="left">17/29 (59%)</td><td align="left">0&#x000b7;83</td></tr><tr><td/><td align="left">Parental consanguinity</td><td align="left">6 (6%)</td><td align="left">3/6 (50%)</td><td align="left">3/6 (50%)</td><td align="left">&#x0003e;0&#x000b7;99</td></tr><tr><td colspan="2" align="left">Study enrolment to genome sequencing result (days)</td><td align="left">21 (15&#x02013;23)</td><td align="left">20 (15&#x02013;25)</td><td align="left">21 (15&#x02013;22)</td><td align="left">0&#x000b7;90</td></tr><tr><td colspan="2" align="left">Age at genome sequencing result (days)</td><td align="left">172 (91&#x02013;250)</td><td align="left">140 (60&#x02013;231)</td><td align="left">204 (126&#x02013;265)</td><td align="left">0&#x000b7;0245</td></tr></tbody></table><table-wrap-foot><fn><p>Data are n (%), n/N (%), or median (IQR), unless otherwise specified. DEE=developmental and epileptic encephalopathy.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fn1"><label>*</label><p id="cenpara10">Uncorrected p value calculated using two-tailed &#x003c7;<sup>2</sup>, Fisher's exact, or Mann-Whitney test, as appropriate.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fn2"><label>&#x02020;</label><p id="cenpara20">Comparing genetic diagnosis versus no genetic diagnosis across the three categories of referral source.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fn3"><label>&#x02021;</label><p id="cenpara30">Comparing genetic diagnosis versus no genetic diagnosis across the four categories of seizure type at onset.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fn4"><label>&#x000a7;</label><p id="cenpara40">Comparing genetic diagnosis versus no genetic diagnosis across the three main categories of epilepsy syndrome at onset (self-limited epilepsies, DEEs, and other).</p></fn></table-wrap-foot></table-wrap></p><p id="para220">Median time from seizure onset to site presentation was 7 days (IQR 1&#x02013;24), from site presentation to enrolment was 3 days (1&#x02013;9), from enrolment to proband sample collection was 0 days (0&#x02013;1), and from sample collection to rapid genome sequencing result was 20 days (14&#x02013;22; <xref rid="fig2" ref-type="fig">figure 2A</xref>). 91 (91%) of 100 families had trio genome sequencing, eight (8%) had duo genome sequencing, and one (1%) had singleton genome sequencing. Median study turnaround time from enrolment to rapid genome sequencing result was 21 days (IQR 15&#x02013;23), shorter at one site (BCH) than the others (median 15 days <italic>vs</italic> 21&#x02013;25 days; adjusted p&#x0003c;0&#x000b7;05 for pairwise comparisons) and not significantly different between referral settings. Median time from seizure onset to rapid genome sequencing result was 37 days (IQR 25&#x02013;59) and median age at rapid genome sequencing result was 172 days (91&#x02013;250), following median age at seizure onset of 128 days (<xref rid="sec1" ref-type="sec">appendix pp 4, 14&#x02013;17</xref>).<fig id="fig2"><label>Figure 2</label><caption><p>Rapid GS workflow and summary of genetic diagnoses</p><p>(A) Rapid GS workflow and time intervals, created with BioRender.com. (B) Genetic diagnoses arranged by age at seizure onset. Each square represents an infant who received a genetic diagnosis. The affected gene or genomic region is denoted in the square. The infant with a diagnostic <italic>SCN2A</italic> variant and seizure onset in the second month of life classified as self-limited neonatal epilepsy was born prematurely and was younger than 44 weeks postmenstrual age at seizure onset. (C) Types of variants in diagnostic cases. Data are n (%) of 46 total variants. (D) Mode of inheritance of variants in diagnostic cases. Data are n (%) of 43 total diagnoses. GS=genome sequencing. DEE=developmental and epileptic encephalopathy.</p></caption><graphic xlink:href="gr2"/></fig></p><p id="para230">We identified genetic diagnoses for 43 (43% [binomial distribution 95% CI 33&#x02013;53]) of 100 infants with new-onset epilepsy (<xref rid="tbl2" ref-type="table">table 2</xref>), with similar yield across sites (41&#x02013;45%) and varied yield by referral setting: 12 (71%) of 17 for intensive care, 19 (44%) of 43 non-intensive care inpatient, and 12 (30%) of 40 outpatient (p=0&#x000b7;0178). 39 (91%) of 43 infants had pathogenic or likely pathogenic variants and four (9%) had variants of uncertain significance considered clinically diagnostic. Infants with diagnostic rapid genome sequencing were younger at seizure onset than were infants with non-diagnostic rapid genome sequencing (median 105 days <italic>vs</italic> 153 days; p=0&#x000b7;0163). Diagnostic yield was higher in infants with neonatal-onset seizures versus infantile-onset seizures (14 [74%] of 19 <italic>vs</italic> 29 [36%] of 81; p=0&#x000b7;0027), with previous developmental delay versus without previous developmental delay (11 [55%] of 20 <italic>vs</italic> 18 [30%] of 61; p=0&#x000b7;0391), and with abnormal head size versus normocephaly (seven [88%] of eight <italic>vs</italic> 36 [39%] of 92; p=0&#x000b7;0195). Diagnostic yield varied by epilepsy syndrome: 13 (87%) of 15 for self-limited epilepsy; 18 (35%) of 51 for developmental and epileptic encephalopathies, including seven (54%) of 13 with early infantile developmental and epileptic encephalopathy and six (19%) of 32 with infantile epileptic spasms syndrome; and 12 (35%) of 34 for other syndromes, including 11 (35%) of 31 with unclassified epilepsy and one (33%) of three with complex febrile seizures (p=0&#x000b7;001; <xref rid="tbl1" ref-type="table">table 1</xref>).<table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Genetic diagnoses made by rapid genome sequencing</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="left"><bold>Sex</bold></th><th align="left"><bold>Referral source</bold></th><th align="left"><bold>Age at onset (days)</bold></th><th align="left"><bold>Age at results (days)</bold></th><th align="left"><bold>Epilepsy syndrome</bold></th><th align="left"><bold>Developmental delay</bold></th><th align="left"><bold>Developmental regression</bold></th><th align="left"><bold>Other clinical features</bold></th><th align="left"><bold>Gene or cytoband</bold></th><th align="left"><bold>Variant</bold></th><th align="left"><bold>Zygosity</bold></th><th align="left"><bold>Inheritance</bold></th><th align="left"><bold>Classifi-cation</bold></th><th align="left"><bold>Other genetic testing (non-diagnostic unless otherwise noted)</bold></th></tr></thead><tbody><tr><td align="left">001</td><td align="left">Male</td><td align="left">NICU</td><td align="left">4</td><td align="left">26</td><td align="left">EIDEE</td><td align="left">NA</td><td align="left">NA</td><td align="left">Unilateral PMG</td><td align="left"><italic>DEPDC5</italic></td><td align="left">c.3061del, p.I1021Ffs*58</td><td align="left">Het</td><td align="left">Maternal</td><td align="left">P</td><td align="left">Previous CMA</td></tr><tr><td align="left">002</td><td align="left">Male</td><td align="left">Inpatient</td><td align="left">224</td><td align="left">241</td><td align="left">IESS</td><td align="left">Yes</td><td align="left">No</td><td align="left">Hypotonia</td><td align="left"><italic>DYNC1H1</italic></td><td align="left">c.6989G&#x0003e;A, p.G2330E</td><td align="left">Het</td><td align="left">De novo</td><td align="left">LP</td><td align="left">Concurrent CMA, panel</td></tr><tr><td align="left">011</td><td align="left">Male</td><td align="left">Inpatient</td><td align="left">42</td><td align="left">120</td><td align="left">EIDEE</td><td align="left">Yes</td><td align="left">No</td><td align="left">MCD</td><td align="left"><italic>TNPO2</italic></td><td align="left">c.466G&#x0003e;A, p.D156N</td><td align="left">Het</td><td align="left">De novo</td><td align="left">P</td><td align="left">..</td></tr><tr><td align="left">014</td><td align="left">Female</td><td align="left">Inpatient</td><td align="left">64</td><td align="left">81</td><td align="left">EIDEE</td><td align="left">No</td><td align="left">No</td><td align="left">..</td><td align="left"><italic>PPP3CA</italic></td><td align="left">c.1255_1256del, p.S419Cfs*31</td><td align="left">Het</td><td align="left">De novo</td><td align="left">P</td><td align="left">Concurrent CMA</td></tr><tr><td align="left">015</td><td align="left">Male</td><td align="left">Inpatient</td><td align="left">149</td><td align="left">161</td><td align="left">IESS</td><td align="left">No</td><td align="left">No</td><td align="left">MCD</td><td align="left"><italic>PTEN</italic></td><td align="left">c.49C&#x0003e;T, p.Q17<xref rid="tbl2fn1" ref-type="table-fn">*</xref></td><td align="left">Het</td><td align="left">De novo</td><td align="left">P</td><td align="left">..</td></tr><tr><td align="left">016</td><td align="left">Male</td><td align="left">NICU</td><td align="left">1</td><td align="left">37</td><td align="left">Focal</td><td align="left">NA</td><td align="left">NA</td><td align="left">Premature (33 weeks), hypotonia, AMC</td><td align="left"><italic>DMPK</italic></td><td align="left">c.*224_226CTG[&#x0003e;200]</td><td align="left">Het</td><td align="left">Maternal<xref rid="tbl2fn1" ref-type="table-fn">*</xref></td><td align="left">P</td><td align="left">Previous CMA, rES, mito</td></tr><tr><td align="left">018</td><td align="left">Female</td><td align="left">Inpatient</td><td align="left">123</td><td align="left">155</td><td align="left">DS-like</td><td align="left">Yes</td><td align="left">No</td><td align="left">Hypotonia</td><td align="left">2q24.2q24.3</td><td align="left">Deletion</td><td align="left">Het</td><td align="left">De novo</td><td align="left">P</td><td align="left">..</td></tr><tr><td align="left">021</td><td align="left">Female</td><td align="left">Outpatient</td><td align="left">291</td><td align="left">357</td><td align="left">SeLIE</td><td align="left">No</td><td align="left">No</td><td align="left">..</td><td align="left"><italic>SCN8A</italic></td><td align="left">c.3926G&#x0003e;A, p.R1309Q</td><td align="left">Het</td><td align="left">De novo</td><td align="left">P</td><td align="left">..</td></tr><tr><td align="left">026</td><td align="left">Male</td><td align="left">Inpatient</td><td align="left">251</td><td align="left">271</td><td align="left">IESS</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Hypotonia, DF</td><td align="left"><italic>SETD5</italic></td><td align="left">c.1967T&#x0003e;G, p.L656<xref rid="tbl2fn1" ref-type="table-fn">*</xref></td><td align="left">Het</td><td align="left">De novo</td><td align="left">P</td><td align="left">..</td></tr><tr><td align="left">027</td><td align="left">Female</td><td align="left">NICU</td><td align="left">1</td><td align="left">20</td><td align="left">Focal</td><td align="left">NA</td><td align="left">NA</td><td align="left">Hypertonia, DF</td><td align="left"><italic>ZC4H2</italic></td><td align="left">c.450del, p.I151Sfs*36</td><td align="left">Het</td><td align="left">De novo</td><td align="left">P</td><td align="left">..</td></tr><tr><td align="left">028</td><td align="left">Female</td><td align="left">NICU</td><td align="left">35</td><td align="left">58</td><td align="left">SeLNE</td><td align="left">NA</td><td align="left">NA</td><td align="left">Premature (33 weeks)</td><td align="left"><italic>SCN2A</italic></td><td align="left">c.662T&#x0003e;C, p.V221A</td><td align="left">Het</td><td align="left">De novo</td><td align="left">LP</td><td align="left">..</td></tr><tr><td align="left">029</td><td align="left">Male</td><td align="left">NICU</td><td align="left">10</td><td align="left">28</td><td align="left">EIDEE</td><td align="left">NA</td><td align="left">NA</td><td align="left">Callosal dysgenesis, hypotonia, DF, PRS</td><td align="left"><italic>MOGS</italic></td><td align="left">c.[1461G&#x0003e;C];[2470G&#x0003e;A], p.[E487D];[G824S]</td><td align="left">Comp het</td><td align="left">Maternal; paternal</td><td align="left">LP; VUS<xref rid="tbl2fn2" ref-type="table-fn">&#x02020;</xref></td><td align="left">Previous prenatal karyotype, CMA</td></tr><tr><td align="left">030</td><td align="left">Male</td><td align="left">PICU</td><td align="left">48</td><td align="left">73</td><td align="left">EIDEE</td><td align="left">NA</td><td align="left">NA</td><td align="left">Premature (36 weeks), DF</td><td align="left"><italic>MOCS2</italic></td><td align="left">c.226G&#x0003e;A, p.G76R</td><td align="left">Hom</td><td align="left">Both</td><td align="left">P</td><td align="left">Previous CMA</td></tr><tr><td align="left">032</td><td align="left">Female</td><td align="left">Inpatient</td><td align="left">126</td><td align="left">155</td><td align="left">Focal</td><td align="left">No</td><td align="left">No</td><td align="left">..</td><td align="left"><italic>CSNK2B</italic></td><td align="left">c.557G&#x0003e;A, p.R186K</td><td align="left">Het</td><td align="left">De novo</td><td align="left">LP</td><td align="left">..</td></tr><tr><td align="left">034</td><td align="left">Female</td><td align="left">NICU</td><td align="left">115</td><td align="left">139</td><td align="left">SeLIe</td><td align="left">No</td><td align="left">No</td><td align="left">..</td><td align="left"><italic>SCN2A</italic></td><td align="left">c.5287T&#x0003e;A, p.S1763T</td><td align="left">Het</td><td align="left">Paternal<xref rid="tbl2fn1" ref-type="table-fn">*</xref></td><td align="left">VUS<xref rid="tbl2fn3" ref-type="table-fn">&#x02021;</xref></td><td align="left">..</td></tr><tr><td align="left">035</td><td align="left">Male</td><td align="left">Outpatient</td><td align="left">66</td><td align="left">144</td><td align="left">Focal</td><td align="left">No</td><td align="left">No</td><td align="left">..</td><td align="left"><italic>STXBP1</italic></td><td align="left">c.260T&#x0003e;C, p.L87P</td><td align="left">Het</td><td align="left">De novo</td><td align="left">LP</td><td align="left">Concurrent CMA, panel (identified)</td></tr><tr><td align="left">037</td><td align="left">Male</td><td align="left">NICU</td><td align="left">18</td><td align="left">61</td><td align="left">EIDEE</td><td align="left">NA</td><td align="left">NA</td><td align="left">Premature (31 weeks), hypotonia, DF</td><td align="left"><italic>BRAT1</italic></td><td align="left">c.[1593G&#x0003e;A];[294dup], p.[W531*];[L99Tfs*92]</td><td align="left">Comp het</td><td align="left">Maternal; paternal</td><td align="left">P; P</td><td align="left">Concurrent CMA</td></tr><tr><td align="left">039</td><td align="left">Male</td><td align="left">Outpatient</td><td align="left">121</td><td align="left">386</td><td align="left">Other</td><td align="left">No</td><td align="left">Yes</td><td align="left">..</td><td align="left"><italic>GABRB3</italic></td><td align="left">c.238A&#x0003e;G, p.M80V</td><td align="left">Het</td><td align="left">De novo</td><td align="left">LP</td><td align="left">Concurrent CMA, panel (identified)</td></tr><tr><td align="left">041</td><td align="left">Male</td><td align="left">Inpatient</td><td align="left">99</td><td align="left">130</td><td align="left">SeLIE</td><td align="left">No</td><td align="left">No</td><td align="left">..</td><td align="left"><italic>KCNQ2</italic></td><td align="left">c.998G&#x0003e;A, p.R333Q</td><td align="left">Het</td><td align="left">De novo</td><td align="left">P</td><td align="left">Concurrent panel (identified)</td></tr><tr><td align="left">045</td><td align="left">Male</td><td align="left">Outpatient</td><td align="left">206</td><td align="left">266</td><td align="left">Other</td><td align="left">No</td><td align="left">Yes</td><td align="left">Axial hypotonia</td><td align="left"><italic>POLR3B</italic></td><td align="left">c.1765G&#x0003e;A, p.G589R</td><td align="left">Het</td><td align="left">De novo</td><td align="left">VUS<xref rid="tbl2fn4" ref-type="table-fn">&#x000a7;</xref></td><td align="left">Concurrent panel</td></tr><tr><td align="left">046</td><td align="left">Female</td><td align="left">Outpatient</td><td align="left">16</td><td align="left">47</td><td align="left">Other</td><td align="left">NA</td><td align="left">NA</td><td align="left">..</td><td align="left">2q24.3q32.1</td><td align="left">Duplication</td><td align="left">Het</td><td align="left">Mosaic</td><td align="left">P</td><td align="left">Concurrent CMA (identified), panel (identified)</td></tr><tr><td align="left">050</td><td align="left">Female</td><td align="left">Inpatient</td><td align="left">138</td><td align="left">160</td><td align="left">DEE</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Dystonia, OA</td><td align="left"><italic>ATP6V1A</italic></td><td align="left">c.761G&#x0003e;A, p.C254Y</td><td align="left">Het</td><td align="left">De novo</td><td align="left">LP</td><td align="left">Concurrent CMA, ES (identified)</td></tr><tr><td align="left">052</td><td align="left">Female</td><td align="left">Outpatient</td><td align="left">27</td><td align="left">52</td><td align="left">DEE</td><td align="left">No</td><td align="left">Yes</td><td align="left">..</td><td align="left"><italic>CDKL5</italic></td><td align="left">c.1648C&#x0003e;T, p.R550<xref rid="tbl2fn1" ref-type="table-fn">*</xref></td><td align="left">Het</td><td align="left">De novo</td><td align="left">P</td><td align="left">Concurrent CMA, panel (identified)</td></tr><tr><td align="left">054</td><td align="left">Male</td><td align="left">Outpatient</td><td align="left">86</td><td align="left">128</td><td align="left">IESS</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Premature (36 weeks), dyskinesia</td><td align="left"><italic>STXBP1</italic></td><td align="left">c.703C&#x0003e;T, p.R235<xref rid="tbl2fn1" ref-type="table-fn">*</xref></td><td align="left">Het</td><td align="left">De novo</td><td align="left">P</td><td align="left">Concurrent CMA, panel (identified)</td></tr><tr><td align="left">056</td><td align="left">Female</td><td align="left">Outpatient</td><td align="left">108</td><td align="left">167</td><td align="left">DEE</td><td align="left">No</td><td align="left">Yes</td><td align="left"><bold>..</bold></td><td align="left"><italic>SCN8A</italic></td><td align="left">c.5615G&#x0003e;A, p.R1872Q</td><td align="left">Het</td><td align="left">De novo</td><td align="left">P</td><td align="left">Concurrent CMA, panel (identified)</td></tr><tr><td align="left">058</td><td align="left">Male</td><td align="left">Inpatient</td><td align="left">53</td><td align="left">110</td><td align="left">Focal</td><td align="left">No</td><td align="left">No</td><td align="left">MCD</td><td align="left"><italic>TSC2</italic></td><td align="left">c.3598C&#x0003e;T, p.R1200W</td><td align="left">Het</td><td align="left">Maternal<xref rid="tbl2fn1" ref-type="table-fn">*</xref></td><td align="left">P</td><td align="left">..</td></tr><tr><td align="left">060</td><td align="left">Male</td><td align="left">Inpatient</td><td align="left">146</td><td align="left">169</td><td align="left">SeLIE</td><td align="left">No</td><td align="left">No</td><td align="left">..</td><td align="left"><italic>PRRT2</italic></td><td align="left">c.649dup, p.R217Pfs*8</td><td align="left">Het</td><td align="left">Maternal<xref rid="tbl2fn5" ref-type="table-fn">&#x000b6;</xref></td><td align="left">P</td><td align="left">..</td></tr><tr><td align="left">061</td><td align="left">Female</td><td align="left">Inpatient</td><td align="left">114</td><td align="left">140</td><td align="left">Focal</td><td align="left">Yes</td><td align="left">No</td><td align="left">..</td><td align="left">18p11.32p11.21</td><td align="left">Deletion</td><td align="left">Het</td><td align="left">De novo</td><td align="left">P</td><td align="left">Concurrent CMA (identified)</td></tr><tr><td align="left">065</td><td align="left">Female</td><td align="left">Inpatient</td><td align="left">0</td><td align="left">53</td><td align="left">SeLNE</td><td align="left">NA</td><td align="left">NA</td><td align="left">VSD</td><td align="left">2q24.1q24.3</td><td align="left">Duplication</td><td align="left">Het</td><td align="left">Unknown</td><td align="left">P</td><td align="left">..</td></tr><tr><td align="left">067</td><td align="left">Female</td><td align="left">Outpatient</td><td align="left">326</td><td align="left">362</td><td align="left">CFS</td><td align="left">Yes</td><td align="left">No</td><td align="left">Hypotonia</td><td align="left"><italic>RRAS2</italic></td><td align="left">c.68G&#x0003e;A, p.G23D</td><td align="left">Het</td><td align="left">De novo</td><td align="left">P</td><td align="left">Previous CMA and fragile X</td></tr><tr><td align="left">073</td><td align="left">Male</td><td align="left">Inpatient</td><td align="left">209</td><td align="left">235</td><td align="left">SeLIE</td><td align="left">No</td><td align="left">No</td><td align="left">..</td><td align="left">16p11.2</td><td align="left">Deletion</td><td align="left">Het</td><td align="left">Not maternal</td><td align="left">P</td><td align="left">..</td></tr><tr><td align="left">074</td><td align="left">Male</td><td align="left">PICU</td><td align="left">251</td><td align="left">287</td><td align="left">DS</td><td align="left">No</td><td align="left">No</td><td align="left">..</td><td align="left"><italic>SCN1A</italic></td><td align="left">c.4867G&#x0003e;C, p.E1623Q</td><td align="left">Het</td><td align="left">Maternal<xref rid="tbl2fn1" ref-type="table-fn">*</xref></td><td align="left">LP</td><td align="left">..</td></tr><tr><td align="left">076</td><td align="left">Male</td><td align="left">Inpatient</td><td align="left">1</td><td align="left">99</td><td align="left">Focal</td><td align="left">NA</td><td align="left">NA</td><td align="left">MCD, abnormal tone, movement disorder, microcephaly</td><td align="left"><italic>TUBA1A</italic></td><td align="left">c.168_171delinsAGCATTCAGAGAT,p.G57delinsAFRD</td><td align="left">Het</td><td align="left">De novo</td><td align="left">LP</td><td align="left">..</td></tr><tr><td align="left">078</td><td align="left">Male</td><td align="left">Inpatient</td><td align="left">163</td><td align="left">227</td><td align="left">IESS</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Hypotonia</td><td align="left">9pterq22.33; 15q22.2qter</td><td align="left">Duplication; duplication</td><td align="left">Het</td><td align="left">Mosaic</td><td align="left">P</td><td align="left">Concurrent CMA</td></tr><tr><td align="left">082</td><td align="left">Female</td><td align="left">Outpatient</td><td align="left">2</td><td align="left">91</td><td align="left">SeLNE</td><td align="left">NA</td><td align="left">NA</td><td align="left">..</td><td align="left"><italic>KCNQ2</italic></td><td align="left">c.1955del, p.P652Rfs*278</td><td align="left">Het</td><td align="left">Maternal</td><td align="left">LP</td><td align="left">Concurrent panel (identified)</td></tr><tr><td align="left">084</td><td align="left">Male</td><td align="left">Inpatient</td><td align="left">119</td><td align="left">145</td><td align="left">SeLIE</td><td align="left">No</td><td align="left">No</td><td align="left">..</td><td align="left"><italic>PRRT2</italic></td><td align="left">c.649C&#x0003e;T, p.R217<xref rid="tbl2fn1" ref-type="table-fn">*</xref></td><td align="left">Het</td><td align="left">Maternal<xref rid="tbl2fn1" ref-type="table-fn">*</xref></td><td align="left">P</td><td align="left">Concurrent CMA</td></tr><tr><td align="left">086</td><td align="left">Female</td><td align="left">Inpatient</td><td align="left">243</td><td align="left">287</td><td align="left">SeLIE</td><td align="left">Yes</td><td align="left">No</td><td align="left">Hypotonia</td><td align="left"><italic>DEAF1</italic></td><td align="left">c.709C&#x0003e;A, p.P237T</td><td align="left">Het</td><td align="left">De novo</td><td align="left">LP</td><td align="left">Concurrent CMA, panel</td></tr><tr><td align="left">088</td><td align="left">Female</td><td align="left">Outpatient</td><td align="left">105</td><td align="left">275</td><td align="left">IESS</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left"><italic>KCNJ6</italic></td><td align="left">c.235G&#x0003e;A, p.D79N</td><td align="left">Het</td><td align="left">De novo</td><td align="left">VUS<xref rid="tbl2fn3" ref-type="table-fn">&#x02021;</xref></td><td align="left">Concurrent CMA</td></tr><tr><td align="left">091</td><td align="left">Female</td><td align="left">Outpatient</td><td align="left">152</td><td align="left">274</td><td align="left">SeLIE</td><td align="left">No</td><td align="left">No</td><td align="left">..</td><td align="left">16p11.2</td><td align="left">Deletion</td><td align="left">Het</td><td align="left">De novo</td><td align="left">P</td><td align="left">Concurrent CMA (identified), panel</td></tr><tr><td align="left">092</td><td align="left">Male</td><td align="left">NICU</td><td align="left">5</td><td align="left">45</td><td align="left">EIDEE</td><td align="left">NA</td><td align="left">NA</td><td align="left">Hypoplastic corpus callosum, hypotonia, club feet, macrocephaly, ASD</td><td align="left"><italic>SCN2A</italic></td><td align="left">c.415A&#x0003e;G, p.I139V</td><td align="left">Het</td><td align="left">Mosaic</td><td align="left">LP</td><td align="left">Concurrent CMA, panel (identified but classified as VUS)</td></tr><tr><td align="left">093</td><td align="left">Male</td><td align="left">Inpatient</td><td align="left">189</td><td align="left">213</td><td align="left">SeLIE</td><td align="left">No</td><td align="left">No</td><td align="left">..</td><td align="left"><italic>SCN8A</italic></td><td align="left">c.4441A&#x0003e;G, p.M1481V</td><td align="left">Het</td><td align="left">Maternal<xref rid="tbl2fn1" ref-type="table-fn">*</xref></td><td align="left">LP</td><td align="left">..</td></tr><tr><td align="left">099</td><td align="left">Male</td><td align="left">NICU</td><td align="left">10</td><td align="left">39</td><td align="left">Other</td><td align="left">NA</td><td align="left">NA</td><td align="left">Premature (32 weeks), abnormal tone</td><td align="left"><italic>SLC6A5</italic></td><td align="left">c.296_297del, p.E99Gfs*22</td><td align="left">Hom</td><td align="left">Both</td><td align="left">P</td><td align="left">Concurrent panel</td></tr><tr><td align="left">100</td><td align="left">Female</td><td align="left">NICU</td><td align="left">4</td><td align="left">24</td><td align="left">SeLFNIE</td><td align="left">NA</td><td align="left">NA</td><td align="left">..</td><td align="left"><italic>KCNQ3</italic></td><td align="left">c.988C&#x0003e;T, p.R330C</td><td align="left">Het</td><td align="left">Paternal<xref rid="tbl2fn1" ref-type="table-fn">*</xref></td><td align="left">P</td><td align="left">Concurrent panel (identified)</td></tr></tbody></table><table-wrap-foot><fn><p>AMC=arthrogryposis multiplex congenita. ASD=atrial septal defect. CFS=complex febrile seizures. CMA=chromosomal microarray. Comp het=compound heterozygous. DF=dysmorphic features. DS=Dravet syndrome. EIDEE=early infantile developmental and epileptic encephalopathy. ES=exome sequencing. GA=gestational age. Het=heterozygous. Hom=homozygous. IESS=infantile epileptic spasms syndrome. LP=likely pathogenic. MCD=malformation of cortical development. Mito=mitochondrial sequencing. NA=not applicable. NICU=neonatal intensive care unit. OA=optic atrophy. P=pathogenic. PICU=paediatric intensive care unit. PMG=polymicrogyria. PRS=Pierre Robin sequence. rES=rapid exome sequencing. SeLFNIE=self-limited familial neonatal-infantile epilepsy. SeLIE=self-limited infantile epilepsy. SeLNE=self-limited neonatal epilepsy. VSD=ventricular septal defect. VUS=variant of uncertain significance.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fn1"><label>*</label><p id="cenpara50">Parent from whom variant was inherited was also affected.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fn2"><label>&#x02020;</label><p id="cenpara60">Confirmed biochemically.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fn3"><label>&#x02021;</label><p id="cenpara70">Considered clinically diagnostic by clinical team.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fn4"><label>&#x000a7;</label><p id="cenpara80">Subsequently found to have abnormal nerve conduction testing.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fn5"><label>&#x000b6;</label><p id="cenpara90">Parent from whom variant was inherited was suspected to also be affected.</p></fn></table-wrap-foot></table-wrap></p><p id="para240">The genetic diagnoses were heterogeneous, with only seven genes or chromosomal regions implicated more than once and 34 unique genes or genomic regions implicated (<xref rid="fig2" ref-type="fig">figure 2B</xref>). Of the 46 pathogenic variants, 37 (80%) were single nucleotide variants or small insertions or deletions, eight (18%) were copy number variants, and one (2%) was a short tandem repeat expansion (<xref rid="fig2" ref-type="fig">figure 2C</xref>). The most common inheritance mode was de novo autosomal dominant (ie, only one allele needed to be affected to cause disease; 25 [58%] of 43, including three cases with mosaic variants), followed by inherited autosomal dominant (ten [23%]; eight [80%] of ten parents were affected or suspected to be affected, of whom two [25%] learned they were affected through this study), autosomal recessive (four [9%]), and de novo X-linked (two [5%]); two (5%) were autosomal dominant with unknown inheritance (<xref rid="fig2" ref-type="fig">figure 2D</xref>).</p><p id="para250">In 15 cases, rapid genome sequencing identified genetic diagnoses not made by site-specific standard of care clinical testing (<xref rid="tbl2" ref-type="table">table 2</xref>): five (33%) with previous non-diagnostic testing and ten (67%) with concurrent non-diagnostic testing. In one infant, rapid genome sequencing detected a mosaic copy number variant (validated with karyotype) not identified on chromosomal microarray. In another infant, singleton gene panel identified a <italic>SCN2A</italic> variant classified as a variant of uncertain significance; trio rapid genome sequencing identified the variant as de novo, leading to the classification as likely pathogenic and facilitating immediate management changes.</p><p id="para260">Of the 57 infants with non-diagnostic genome sequencing, ten (18%) had variants of uncertain significance in genes potentially relevant to phenotypes (<xref rid="sec1" ref-type="sec">appendix pp 18&#x02013;24</xref>). Secondary or incidental diagnostic findings were detected in five (5%) of 100 infants (<xref rid="sec1" ref-type="sec">appendix pp 25&#x02013;26</xref>).</p><p id="para270">Clinical utility was present for 42 (98%) of 43 infants with genetic diagnoses (<xref rid="tbl3" ref-type="table">table 3</xref>; <xref rid="sec1" ref-type="sec">appendix pp 27&#x02013;28</xref>). In one (2%) of 43 infants (case 099), the genetic diagnosis led to a new clinical diagnosis: an infant initially diagnosed with clinical seizures was also diagnosed with hyperekplexia after detection of a <italic>SLC6A5</italic> variant. Genetic diagnoses influenced treatment, predominantly antiseizure medication selection, in 24 (56%) of 43 infants; implicated potential precision therapies, regardless of whether used, in 21 (49%); and led to additional evaluation in 28 (65%; all had new subspecialty referrals and 11 [39%] of 28 new imaging or laboratory tests). Further evaluation was avoided for eight (19%) of 43 infants. In 37 (86%) of 43 infants, genetic diagnoses informed prognosis beyond that based on the epilepsy diagnosis (eg, likelihood of intellectual disability). For two (5%) of 43 infants (<italic>MOGS</italic>-congenital disorder of glycosylation and <italic>BRAT1</italic>-lethal neonatal rigidity and multifocal seizure syndrome), the genetic diagnoses supported decision making to redirect care to palliation. All families received genetic counselling, including recurrence risk counselling; 12 (28%) of 43 infants had genetic diagnoses that had health implications for parents or led to referral of additional family members for genetic testing. For non-diagnostic and secondary or incidental rapid genome sequencing results, clinical utility was present for 13 (23%) of 57 infants (<xref rid="sec1" ref-type="sec">appendix pp 27&#x02013;28</xref>). In one infant (case 085), non-diagnostic rapid genome sequencing supported decision making to redirect care to palliation by helping to rule out potentially treatable aetiologies.<table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>Utility of genetic diagnoses</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="left"><bold>Gene</bold></th><th align="left"><bold>Any utility</bold></th><th align="left"><bold>Influence treatment</bold></th><th align="left"><bold>New workup</bold></th><th align="left"><bold>Avoid workup</bold></th><th align="left"><bold>Inform prognosis</bold></th><th align="left"><bold>Inform goals of care</bold></th><th align="left"><bold>Inform genetic counselling</bold><xref rid="tbl3fn1" ref-type="table-fn">*</xref></th><th align="left"><bold>Potential precision therapy</bold><xref rid="tbl3fn2" ref-type="table-fn">&#x02020;</xref></th></tr></thead><tbody><tr><td align="left">Total (n=43)</td><td align="left">..</td><td align="left">42 (98%)</td><td align="left">24 (56%)</td><td align="left">28 (65%)</td><td align="left">8 (19%)</td><td align="left">37 (86%)</td><td align="left">2 (5%)</td><td align="left">12 (28%)</td><td align="left">21 (49%)</td></tr><tr><td align="left">001</td><td align="left"><italic>DEPDC5</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">002</td><td align="left"><italic>DYNC1H1</italic></td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">011</td><td align="left"><italic>TNPO2</italic></td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">014</td><td align="left"><italic>PPP3CA</italic></td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">015</td><td align="left"><italic>PTEN</italic></td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td></tr><tr><td align="left">016</td><td align="left"><italic>DMPK</italic></td><td align="left">Yes<xref rid="tbl3fn3" ref-type="table-fn">&#x02021;</xref></td><td align="left">..</td><td align="left">..</td><td align="left">..</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td></tr><tr><td align="left">018</td><td align="left">2q del</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td></tr><tr><td align="left">021</td><td align="left"><italic>SCN8A</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">026</td><td align="left"><italic>SETD5</italic></td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">027</td><td align="left"><italic>ZC4H2</italic></td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">028</td><td align="left"><italic>SCN2A</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td></tr><tr><td align="left">029</td><td align="left"><italic>MOGS</italic></td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td></tr><tr><td align="left">030</td><td align="left"><italic>MOCS2</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">032</td><td align="left"><italic>CSNK2B</italic></td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">034</td><td align="left"><italic>SCN2A</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td></tr><tr><td align="left">035</td><td align="left"><italic>STXBP1</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">037</td><td align="left"><italic>BRAT1</italic></td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">039</td><td align="left"><italic>GABRB3</italic></td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">041</td><td align="left"><italic>KCNQ2</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td></tr><tr><td align="left">045</td><td align="left"><italic>POLR3B</italic></td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">046</td><td align="left">2q dup</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td></tr><tr><td align="left">050</td><td align="left"><italic>ATP6V1A</italic></td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">052</td><td align="left"><italic>CDKL5</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">054</td><td align="left"><italic>STXBP1</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">056</td><td align="left"><italic>SCN8A</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td></tr><tr><td align="left">058</td><td align="left"><italic>TSC2</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">060</td><td align="left"><italic>PRRT2</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">061</td><td align="left">18p del</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">065</td><td align="left">2q dup</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td></tr><tr><td align="left">067</td><td align="left"><italic>RRAS2</italic></td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td></tr><tr><td align="left">073</td><td align="left">16p del</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td></tr><tr><td align="left">074</td><td align="left"><italic>SCN1A</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">076</td><td align="left"><italic>TUBA1A</italic></td><td align="left"><bold>..</bold></td><td align="left">..</td><td align="left">..</td><td align="left">..</td><td align="left">..</td><td align="left">..</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">078</td><td align="left">9p dup &#x00026; 15q dup</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">082</td><td align="left"><italic>KCNQ2</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td></tr><tr><td align="left">084</td><td align="left"><italic>PRRT2</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">086</td><td align="left"><italic>DEAF1</italic></td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">088</td><td align="left"><italic>KCNJ6</italic></td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">..</td><td align="left">..</td><td align="left">..</td></tr><tr><td align="left">091</td><td align="left">16p del</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td></tr><tr><td align="left">092</td><td align="left"><italic>SCN2A</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td></tr><tr><td align="left">093</td><td align="left"><italic>SCN8A</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">099</td><td align="left"><italic>SLC6A5</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">100</td><td align="left"><italic>KCNQ3</italic></td><td align="left">Yes</td><td align="left">Yes</td><td align="left">..</td><td align="left">..</td><td align="left">Yes</td><td align="left">..</td><td align="left">Yes</td><td align="left">Yes</td></tr></tbody></table><table-wrap-foot><fn><p>Data are n (%), unless otherwise specified.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fn1"><label>*</label><p id="cenpara100">All families received recurrence risk counselling based on the mode of inheritance of the diagnostic variants. Yes in this column refers to new health implication for parents or referral of additional family members for genetic testing for the diagnostic variants.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fn2"><label>&#x02020;</label><p id="cenpara110">Implication for precision treatment based on the genetic aetiology regardless of whether the treatment was used.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fn3"><label>&#x02021;</label><p id="cenpara120">Diagnosis did not have direct utility for this case as the infant died before the rapid genome sequencing result was available.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="cesec100"><title>Discussion</title><p id="para280">To the best of our knowledge, this international, multicentre Gene-STEPS study is the first study of rapid genomic testing primarily outside an intensive care setting and in a disease-specific cohort. We demonstrate feasibility of rapid genome sequencing in infants with new-onset epilepsy across multiple tertiary paediatric systems, with high diagnostic yield and clinical effect. Our findings provide support to prompt the use of state-of-the-art rapid genomic testing to facilitate early aetiological diagnosis that can inform urgent targeted management in this vulnerable population.</p><p id="para290">We demonstrate feasibility of expanding trio rapid genome sequencing from intensive care to outpatient and non-intensive care inpatient settings in four countries, with more than 80% of infants recruited from non-intensive care settings. More than 90% of parents consented, showing their interest in identifying the cause of their infant's seizures through early, rapid, and comprehensive genetic testing. Through the IPCHiP consortium, we harmonised study protocols across sites, strengthening the generalisability of our findings. Despite our sites having expertise in genomics and epilepsy, as well as institutional resources, this study posed challenges, including the cost of rapid genome sequencing and the need for sufficient personnel to efficiently achieve recruitment, research and clinical consent, sample collection, timely laboratory processes, variant interpretation, and return of results. Our experience highlights the need for collaboration between neurologists, geneticists, and genetic counsellors to ensure rapid identification of clinically significant variants to optimise patient care.</p><p id="para300">To our knowledge, this study is the first to evaluate rapid genome sequencing in infants with epilepsy. Our diagnostic yield of 43% is consistent with the yield of non-rapid genome sequencing (48%) in epilepsy reported in a recent systematic review (350 participants mostly with developmental and epileptic encephalopathies or severe phenotypes) and higher than that of chromosomal microarray (9%), gene panels (19%), and exome sequencing (24%), acknowledging that these studies have different inclusion or exclusion criteria.<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> We excluded infants with acquired epilepsies, who would be predicted to have far lower likelihood of genetic aetiologies, and infants with known genetic causes, whose inclusion would have increased the diagnostic yield of rapid genome sequencing. Overall, although our cohort is not population based,<xref rid="bib21" ref-type="bibr">21</xref>, <xref rid="bib22" ref-type="bibr">22</xref> it represents most infants who present to tertiary paediatric centres with unexplained epilepsy. Most of our findings are de novo and could thus be relevant to patients of all ancestries. Nonetheless, a limitation of our study is that most infants have parent-reported White race. Future studies including more diverse populations are needed to achieve broader generalisability.</p><p id="para310">We confirm high diagnostic yield in neonatal-onset epilepsies, self-limited epilepsies, and early infantile developmental and epileptic encephalopathies, with relatively lower, although still important, yield in infantile epileptic spasms syndrome. The varied yield for different epilepsy syndromes highlights the importance of rigorous phenotyping when counselling families. Indeed, in four (29%) of 14 infants with primary findings of variants classified as uncertain significance by standardised criteria, the variants of uncertain significance were considered clinically diagnostic by expert clinicians given phenotype-genotype correlation; in two (50%) of four cases, further clinical investigation confirmed pathogenicity.</p><p id="para320">We also confirm genetic heterogeneity and the importance of channelopathies (15% of cohort) in infantile-onset epilepsies. In contrast to previous studies utilising gene panels or exome sequencing, we did not see clear predominance of a small number of genes (eg, <italic>KCNQ2</italic>, <italic>PRRT2</italic>, and <italic>SCN1A</italic>).<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib7" ref-type="bibr">7</xref>, <xref rid="bib22" ref-type="bibr">22</xref> This finding might reflect that previous studies using gene panels were limited to analysing specific subsets of genes or were conducted before the associations of other genes with epilepsy were identified. A potential limitation of our study is that our findings in a cohort of 100 participants might not reflect the full heterogenous genetic landscape of infantile-onset epilepsies. Furthermore, our study was not powered for a multivariate predictive model to assess which factors best predict a higher likelihood of identifying a genetic diagnosis; a larger cohort would be needed to develop such a model and investigate potential confounders in our analysis.</p><p id="para330">Genome sequencing represents the most comprehensive genetic testing approach but is not yet widely available. In most clinical settings, current standard of care includes chromosomal microarray or gene panel or exome sequencing (including tests performed on an exome sequencing or genome sequencing backbone using next-generation sequencing technology but analysed for only a small number of genes), performed concurrently or sequentially. Although our study was not designed to directly compare rapid genome sequencing with other tests, we demonstrate high yield of genome sequencing, performed as trio rapid genome sequencing whenever biological parents were available, and highlight its ability to detect genetic diagnoses not revealed by other modalities. Our findings support a genome-wide approach (exome sequencing or genome sequencing) as first-line genetic testing in infantile epilepsies, following guidelines endorsed by the American Epilepsy Society.<xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> Future studies are needed to accurately quantify the additional yield of genome sequencing compared with other tests in epilepsy.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> We anticipate that genome sequencing, which can detect single nucleotide variants, copy number variants, and other variant types, will become first-line testing and obviate the need for multiple tests in most patients, with trio rapid genome sequencing further enhancing yield.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref></p><p id="para340">Infants with epilepsy represent a vulnerable population with substantial morbidity and mortality burden. Unlike previous epilepsy cohort studies with exome sequencing or genome sequencing performed in research laboratories,<xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref> we performed rapid genome sequencing in clinically accredited laboratories, allowing immediate return of results to families and clinicians. Clinical utility was present for 55% of the cohort, including 98% with diagnostic rapid genome sequencing and 23% with non-diagnostic rapid genome sequencing or secondary or incidental findings. For participants with diagnostic rapid genome sequencing, we report a higher rate of clinical utility than with previous studies.<xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib12" ref-type="bibr">12</xref>, <xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>, <xref rid="bib15" ref-type="bibr">15</xref> Because of the current follow-up duration, we can only report short-term utility; additional utility is likely to be observed long term. We encourage future studies to report utility of non-diagnostic and secondary or incidental findings, as we found meaningful utility in multiple cases.</p><p id="para350">We identified numerous positive effects of early genetic diagnosis, affecting treatment (56%), evaluation (65%), and prognostic counselling (86%), and suggesting potential precision therapies (49%). In some cases, genetic diagnosis suggested a relatively good prognosis, with high likelihood of weaning antiseizure medication and normal development (eg, <italic>PRRT2</italic>). In other cases, genetic diagnosis suggested a relatively poor prognosis, with high likelihood of drug-resistant seizures, global developmental delay or intellectual disability, and even early mortality (eg, <italic>BRAT1</italic>), thus informing goals of care. Making a precise diagnosis also guides recurrence risk counselling, whether with inherited variants (high risk) or with apparently de novo variants (low but not zero risk due to the inability to detect parental gonadal mosaicism<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref>), which is important to guide reproductive decision making for families.</p><p id="para360">We acknowledge some negative or difficult aspects of rapid genome sequencing. Early genetic diagnosis and awareness of future prognosis might contribute to diagnostic shock and parental stress.<xref rid="bib29" ref-type="bibr">29</xref>, <xref rid="bib30" ref-type="bibr">30</xref> As rapid genome sequencing becomes more widespread, families should be counselled before consenting and supported after results are returned. An important issue is the variable severity of conditions associated with a single gene. For example, <italic>KCNQ2</italic>, <italic>KCNQ3</italic>, <italic>SCN1A</italic>, <italic>SCN2A</italic>, and <italic>SCN8A</italic> are associated with phenotypes ranging from self-limited epilepsies with normal developmental outcome to intermediate severity conditions to drug-resistant epilepsies with profound developmental impairment.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Precise prognostication is not always possible early on, and this uncertainty is very challenging for families. Our findings also included several neurodevelopmental disorders in which developmental impairments and other clinical features might become evident after infancy. Longitudinal evaluation is essential to monitor for additional clinical features and delineate the genetic landscape of epilepsy with and without neurodevelopmental disorders.<xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib31" ref-type="bibr">31</xref></p><p id="para370">An additional area of uncertainty relates to the detection of variants of uncertain significance not considered clinically diagnostic, as was the case for 10% of our cohort, which might require time or additional investigation to resolve. Detection of variants of uncertain significance is a feature of all genomic tests given that our knowledge of the genome and disease associations is incomplete. Exome sequencing or genome sequencing, especially trio, might be associated with fewer variants of uncertain significance than gene panel testing.<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref></p><p id="para380">Finally, trio rapid genome sequencing can identify secondary or incidental diagnostic findings in the infant and, thus, parents, as occurred in 5% of our cohort. Parents require adequate pre-test counselling regarding this possibility and post-test support for coping with unexpected familial health implications.</p><p id="para390">The turnaround time of rapid genome sequencing has recently been reported to be on the order of hours in intensive care settings, compared with weeks in our study, suggesting room for improvement.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref> However, given the inclusion of participants from both inpatient and outpatient settings, and the baseline lack of access to rapid&#x02014;or any&#x02014;genomic sequencing for many participants, a median turnaround time of 21 days from study enrolment to rapid genome sequencing result represents a major improvement over current standard of care. Moreover, although we aimed to perform trio genome sequencing for all individuals, for nine (9%) of 100 infants we were only able to perform duo or singleton genome sequencing. Although this approach might reduce opportunities for genetic diagnosis and discovery relative to trio testing, we believe these options are essential for ensuring equitable access when biological parents are unavailable.</p><p id="para400">We focused on initial diagnostic yield and short-term impact of rapid genome sequencing. Longitudinal follow-up will be essential to demonstrating the importance of rapid diagnosis in improving clinical, quality of life, and economic outcomes, which will inform advocacy and policy decisions about funding of genetic testing. Further aspects to assess include the parental perspective regarding rapid genome sequencing to ensure acceptability for those most likely to benefit from early diagnoses, reanalysis of genome sequencing data to increase diagnostic yield over time, and implementation of rapid genome sequencing into routine clinical practice.</p><p id="para410">We demonstrate the success and effect of a collaborative international model to provide rapid genetic diagnosis and clinical utility to infants with epilepsy through prospective enrolment, phenotyping, rapid genome sequencing, interpretation, and return of results. The diagnostic yield and short-term clinical effects are already high, and we anticipate long-term benefits for patients and families. As we shift the paradigm of epilepsy evaluation and diagnosis in the first year of life, this model might serve as a blueprint for advancing precision health for additional diseases whose aetiologies are suspected to be genetic but remain largely unexplained.</p><p id="para11">
<boxed-text id="textbox11"><p id="para12">
<bold>This online publication has been corrected. The corrected version first appeared at thelancet.com/neurology on October 17, 2023</bold>
</p></boxed-text>
</p></sec><sec sec-type="data-availability" id="cesec110"><title>Data sharing</title><p id="para480">Deidentified clinical information included in this analysis and rapid genome sequencing results reported for each participant are provided in the supplementary material. Reported variants were deposited into public databases (eg, ClinVar) per the policies of the clinically accredited laboratories who performed the rapid genome sequencing. The study protocol is available after publication by request. Requests should be addressed to Amy McTague (a.mctague@ucl.ac.uk).</p></sec><sec sec-type="COI-statement" id="conflict-of-interest"><title>Declaration of interests</title><p id="para490">APa is a current member of the National Institute of Health and Clinical excellence (NICE) technology appraisal committee B and has a financial interest in Genedrive PLC. KW has consulted for Stoke Therapeutics. JHC has received renumeration for lectures by GW pharma/Jazz, UCB/Zogenix, Biocodex, and Biogen; is a member of the Data Monitoring and Safety Committee for Admiral Trial (Stroke Therapeutics); and is Chair of the Medical Advisory Board for Matthews Friends, Dravet UK, and Hope for Hypothalamic Hamartoma. IES has served on scientific advisory boards for BioMarin, Chiesi, Eisai, Encoded Therapeutics, GlaxoSmithKline, Knopp Biosciences, Nutricia, Rogcon, Takeda Pharmaceuticals, UCB, and Xenon Pharmaceuticals; has received speaker honoraria from GlaxoSmithKline, UCB, BioMarin, Biocodex, Chiesi, Liva Nova, Nutricia, Zuellig Pharma, and Eisai; has received funding for travel from UCB, Biocodex, GlaxoSmithKline, Biomarin, Encoded Therapeutics, and Eisai; has served as an investigator for Anavex Life Sciences, Cerecin, Cerevel Therapeutics, Eisai, Encoded Therapeutics, EpiMinder, Epygenyx, ES-Therapeutics, GW Pharma, Marinus, Neurocrine BioSciences, Ovid Therapeutics, Takeda Pharmaceuticals, UCB, Ultragenyx, Xenon Pharmaceuticals, Zogenix, and Zynerba; and has consulted for Care Beyond Diagnosis, Epilepsy Consortium, Atheneum Partners, Ovid Therapeutics, UCB, Zynerba Pharmaceuticals, BioMarin, Encoded Therapeutics, and Biohaven Pharmaceuticals; and is a Non-Executive Director of Bellberry and a Director of the Australian Academy of Health and Medical Sciences and the Australian Council of Learned Academies. IES might accrue future revenue on pending patent WO61/010176 (filed in 2008; therapeutic compound); has a patent for <italic>SCN1A</italic> testing held by Bionomics and licensed to various diagnostic companies; has a patent molecular diagnostic or theranostic target for benign familial infantile epilepsy (PRRT2; 2011904493, 2012900190, and PCT/AU2012/001321 [TECH ID:2012-009]). GC has received honorarium from CADTH and serves as the Co-Lead of the Can-GARD Initiative and on the SickKids Precision Child Health steering committee. APo serves on the scientific advisory boards for TevardBio and Syngap Research Fund, and on the American Epilepsy Society Board of Directors. KBH has received support from RogCon Biosciences and Praxis Precision Medicines. AM has received consulting fees from Rocket Pharmaceuticals; honorarium from Jazz Pharmaceuticals; support for attending conferences from Jazz Pharmaceuticals and European Paediatric Neurology Society; fees for participating on boards for Biogen and Biocodex; and serves unpaid roles on the ILAE Genetic Literacy Task Force, EPICARE, and Great Ormond Street Hospital National Institute for Health and Care Research Biomedical Research Centre Chair of Junior Faculty. All other authors declare no competing interests.</p></sec></body><back><ref-list id="bibl10"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sbref10"><person-group person-group-type="author"><name><surname>Zuberi</surname><given-names>SM</given-names></name><name><surname>Wirrell</surname><given-names>E</given-names></name><name><surname>Yozawitz</surname><given-names>E</given-names></name><etal/></person-group><article-title>ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on Nosology and Definitions</article-title><source>Epilepsia</source><volume>63</volume><year>2022</year><fpage>1349</fpage><lpage>1397</lpage><pub-id pub-id-type="pmid">35503712</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sbref20"><person-group person-group-type="author"><name><surname>McTague</surname><given-names>A</given-names></name><name><surname>Howell</surname><given-names>KB</given-names></name><name><surname>Cross</surname><given-names>JH</given-names></name><name><surname>Kurian</surname><given-names>MA</given-names></name><name><surname>Scheffer</surname><given-names>IE</given-names></name></person-group><article-title>The genetic landscape of the epileptic encephalopathies of infancy and childhood</article-title><source>Lancet Neurol</source><volume>15</volume><year>2016</year><fpage>304</fpage><lpage>316</lpage><pub-id pub-id-type="pmid">26597089</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sbref30"><person-group person-group-type="author"><name><surname>Oliver</surname><given-names>KL</given-names></name><name><surname>Scheffer</surname><given-names>IE</given-names></name><name><surname>Bennett</surname><given-names>MF</given-names></name><name><surname>Grinton</surname><given-names>BE</given-names></name><name><surname>Bahlo</surname><given-names>M</given-names></name><name><surname>Berkovic</surname><given-names>SF</given-names></name></person-group><article-title>Genes4Epilepsy: an epilepsy gene resource</article-title><source>Epilepsia</source><volume>64</volume><year>2023</year><fpage>1368</fpage><lpage>1375</lpage><pub-id pub-id-type="pmid">36808730</pub-id>
</element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sbref40"><person-group person-group-type="author"><name><surname>Sheidley</surname><given-names>BR</given-names></name><name><surname>Malinowski</surname><given-names>J</given-names></name><name><surname>Bergner</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Genetic testing for the epilepsies: a systematic review</article-title><source>Epilepsia</source><volume>63</volume><year>2022</year><fpage>375</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">34893972</pub-id>
</element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sbref50"><person-group person-group-type="author"><name><surname>Krey</surname><given-names>I</given-names></name><name><surname>Platzer</surname><given-names>K</given-names></name><name><surname>Esterhuizen</surname><given-names>A</given-names></name><etal/></person-group><article-title>Current practice in diagnostic genetic testing of the epilepsies</article-title><source>Epileptic Disord</source><volume>24</volume><year>2022</year><fpage>765</fpage><lpage>786</lpage><pub-id pub-id-type="pmid">35830287</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sbref60"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>L</given-names></name><name><surname>Malinowski</surname><given-names>J</given-names></name><name><surname>Ceulemans</surname><given-names>S</given-names></name><etal/></person-group><article-title>Genetic testing and counseling for the unexplained epilepsies: an evidence-based practice guideline of the National Society of Genetic Counselors</article-title><source>J Genet Couns</source><volume>32</volume><year>2022</year><fpage>266</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">36281494</pub-id>
</element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sbref70"><person-group person-group-type="author"><name><surname>Symonds</surname><given-names>JD</given-names></name><name><surname>McTague</surname><given-names>A</given-names></name></person-group><article-title>Epilepsy and developmental disorders: next generation sequencing in the clinic</article-title><source>Eur J Paediatr Neurol</source><volume>24</volume><year>2020</year><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">31882278</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sbref80"><person-group person-group-type="author"><name><surname>Shellhaas</surname><given-names>RA</given-names></name><name><surname>Wusthoff</surname><given-names>CJ</given-names></name><name><surname>Tsuchida</surname><given-names>TN</given-names></name><etal/></person-group><article-title>Profile of neonatal epilepsies: characteristics of a prospective US cohort</article-title><source>Neurology</source><volume>89</volume><year>2017</year><fpage>893</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">28733343</pub-id>
</element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sbref90"><person-group person-group-type="author"><name><surname>Smedley</surname><given-names>D</given-names></name><name><surname>Smith</surname><given-names>KR</given-names></name><name><surname>Martin</surname><given-names>A</given-names></name><etal/></person-group><article-title>100&#x02008;000 genomes pilot on rare-disease diagnosis in health care&#x02014;preliminary report</article-title><source>N Engl J Med</source><volume>385</volume><year>2021</year><fpage>1868</fpage><lpage>1880</lpage><pub-id pub-id-type="pmid">34758253</pub-id>
</element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sbref100"><person-group person-group-type="author"><name><surname>Striano</surname><given-names>P</given-names></name><name><surname>Minassian</surname><given-names>BA</given-names></name></person-group><article-title>From genetic testing to precision medicine in epilepsy</article-title><source>Neurotherapeutics</source><volume>17</volume><year>2020</year><fpage>609</fpage><lpage>615</lpage><pub-id pub-id-type="pmid">31981099</pub-id>
</element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sbref110"><person-group person-group-type="author"><name><surname>McKnight</surname><given-names>D</given-names></name><name><surname>Morales</surname><given-names>A</given-names></name><name><surname>Hatchell</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Genetic testing to inform epilepsy treatment management from an international study of clinical practice</article-title><source>JAMA Neurol</source><volume>79</volume><year>2022</year><fpage>1267</fpage><lpage>1276</lpage><pub-id pub-id-type="pmid">36315135</pub-id>
</element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sbref120"><person-group person-group-type="author"><name><surname>Haviland</surname><given-names>I</given-names></name><name><surname>Daniels</surname><given-names>CI</given-names></name><name><surname>Greene</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Genetic diagnosis impacts medical management for pediatric epilepsies</article-title><source>Pediatr Neurol</source><volume>138</volume><year>2023</year><fpage>71</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">36403551</pub-id>
</element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sbref130"><person-group person-group-type="author"><name><surname>Bayat</surname><given-names>A</given-names></name><name><surname>Fenger</surname><given-names>CD</given-names></name><name><surname>Techlo</surname><given-names>TR</given-names></name><etal/></person-group><article-title>Impact of genetic testing on therapeutic decision-making in childhood-onset epilepsies&#x02014;a study in a tertiary epilepsy center</article-title><source>Neurotherapeutics</source><volume>19</volume><year>2022</year><fpage>1353</fpage><lpage>1367</lpage><pub-id pub-id-type="pmid">35723786</pub-id>
</element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sbref140"><person-group person-group-type="author"><name><surname>Scheffer</surname><given-names>IE</given-names></name><name><surname>Bennett</surname><given-names>CA</given-names></name><name><surname>Gill</surname><given-names>D</given-names></name><etal/></person-group><article-title>Exome sequencing for patients with developmental and epileptic encephalopathies in clinical practice</article-title><source>Dev Med Child Neurol</source><volume>65</volume><year>2023</year><fpage>50</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">35701389</pub-id>
</element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sbref150"><person-group person-group-type="author"><name><surname>Graifman</surname><given-names>JL</given-names></name><name><surname>Lippa</surname><given-names>NC</given-names></name><name><surname>Mulhern</surname><given-names>MS</given-names></name><name><surname>Bergner</surname><given-names>AL</given-names></name><name><surname>Sands</surname><given-names>TT</given-names></name></person-group><article-title>Clinical utility of exome sequencing in a pediatric epilepsy cohort</article-title><source>Epilepsia</source><volume>64</volume><year>2023</year><fpage>986</fpage><lpage>997</lpage><pub-id pub-id-type="pmid">36740579</pub-id>
</element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sbref160"><person-group person-group-type="author"><name><surname>Berg</surname><given-names>AT</given-names></name><name><surname>Loddenkemper</surname><given-names>T</given-names></name><name><surname>Baca</surname><given-names>CB</given-names></name></person-group><article-title>Diagnostic delays in children with early onset epilepsy: impact, reasons, and opportunities to improve care</article-title><source>Epilepsia</source><volume>55</volume><year>2014</year><fpage>123</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">24313635</pub-id>
</element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sbref170"><person-group person-group-type="author"><name><surname>Diaby</surname><given-names>V</given-names></name><name><surname>Babcock</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Real-world economic evaluation of prospective rapid whole-genome sequencing compared to a matched retrospective cohort of critically ill pediatric patients in the United States</article-title><source>Pharmacogenomics J</source><volume>22</volume><year>2022</year><fpage>223</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">35436997</pub-id>
</element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sbref180"><person-group person-group-type="author"><name><surname>French</surname><given-names>CE</given-names></name><name><surname>Delon</surname><given-names>I</given-names></name><name><surname>Dolling</surname><given-names>H</given-names></name><etal/></person-group><article-title>Whole genome sequencing reveals that genetic conditions are frequent in intensively ill children</article-title><source>Intensive Care Med</source><volume>45</volume><year>2019</year><fpage>627</fpage><lpage>636</lpage><pub-id pub-id-type="pmid">30847515</pub-id>
</element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sbref190"><person-group person-group-type="author"><name><surname>Kingsmore</surname><given-names>SF</given-names></name><name><surname>Cole</surname><given-names>FS</given-names></name></person-group><article-title>The role of genome sequencing in neonatal intensive care units</article-title><source>Annu Rev Genomics Hum Genet</source><volume>23</volume><year>2022</year><fpage>427</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">35676073</pub-id>
</element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sbref200"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>S</given-names></name><name><surname>Aziz</surname><given-names>N</given-names></name><name><surname>Bale</surname><given-names>S</given-names></name><etal/></person-group><article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title><source>Genet Med</source><volume>17</volume><year>2015</year><fpage>405</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">25741868</pub-id>
</element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sbref210"><person-group person-group-type="author"><name><surname>Howell</surname><given-names>KB</given-names></name><name><surname>Eggers</surname><given-names>S</given-names></name><name><surname>Dalziel</surname><given-names>K</given-names></name><etal/></person-group><article-title>A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancy</article-title><source>Epilepsia</source><volume>59</volume><year>2018</year><fpage>1177</fpage><lpage>1187</lpage><pub-id pub-id-type="pmid">29750358</pub-id>
</element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sbref220"><person-group person-group-type="author"><name><surname>Symonds</surname><given-names>JD</given-names></name><name><surname>Zuberi</surname><given-names>SM</given-names></name><name><surname>Stewart</surname><given-names>K</given-names></name><etal/></person-group><article-title>Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort</article-title><source>Brain</source><volume>142</volume><year>2019</year><fpage>2303</fpage><lpage>2318</lpage><pub-id pub-id-type="pmid">31302675</pub-id>
</element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sbref230"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>EE</given-names></name><name><surname>Sachdev</surname><given-names>R</given-names></name><name><surname>Macintosh</surname><given-names>R</given-names></name><etal/></person-group><article-title>Diagnostic yield of whole genome sequencing after nondiagnostic exome sequencing or gene panel in developmental and epileptic encephalopathies</article-title><source>Neurology</source><volume>96</volume><year>2021</year><fpage>e1770</fpage><lpage>e1782</lpage><pub-id pub-id-type="pmid">33568551</pub-id>
</element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sbref240"><person-group person-group-type="author"><name><surname>Manickam</surname><given-names>K</given-names></name><name><surname>McClain</surname><given-names>MR</given-names></name><name><surname>Demmer</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)</article-title><source>Genet Med</source><volume>23</volume><year>2021</year><fpage>2029</fpage><lpage>2037</lpage><pub-id pub-id-type="pmid">34211152</pub-id>
</element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sbref250"><person-group person-group-type="author"><name><surname>Hamdan</surname><given-names>FF</given-names></name><name><surname>Myers</surname><given-names>CT</given-names></name><name><surname>Cossette</surname><given-names>P</given-names></name><etal/></person-group><article-title>High rate of recurrent de novo mutations in developmental and epileptic encephalopathies</article-title><source>Am J Hum Genet</source><volume>101</volume><year>2017</year><fpage>664</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">29100083</pub-id>
</element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sbref260"><person-group person-group-type="author"><collab>Epi25 Collaborative</collab></person-group><article-title>Ultra-rare genetic variation in the epilepsies: a whole-exome sequencing study of 17&#x02008;606 individuals</article-title><source>Am J Hum Genet</source><volume>105</volume><year>2019</year><fpage>267</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">31327507</pub-id>
</element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sbref270"><person-group person-group-type="author"><collab>Epi4K Consortium</collab><collab>Epilepsy Phenome/Genome Project</collab><name><surname>Allen</surname><given-names>AS</given-names></name><etal/></person-group><article-title>De novo mutations in epileptic encephalopathies</article-title><source>Nature</source><volume>501</volume><year>2013</year><fpage>217</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">23934111</pub-id>
</element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sbref280"><person-group person-group-type="author"><name><surname>Myers</surname><given-names>CT</given-names></name><name><surname>Hollingsworth</surname><given-names>G</given-names></name><name><surname>Muir</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Parental mosaicism in &#x0201c;de novo&#x0201d; epileptic encephalopathies</article-title><source>N Engl J Med</source><volume>378</volume><year>2018</year><fpage>1646</fpage><lpage>1648</lpage><pub-id pub-id-type="pmid">29694806</pub-id>
</element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sbref290"><person-group person-group-type="author"><name><surname>Jeffrey</surname><given-names>JS</given-names></name><name><surname>Leathem</surname><given-names>J</given-names></name><name><surname>King</surname><given-names>C</given-names></name><name><surname>Mefford</surname><given-names>HC</given-names></name><name><surname>Ross</surname><given-names>K</given-names></name><name><surname>Sadleir</surname><given-names>LG</given-names></name></person-group><article-title>Developmental and epileptic encephalopathy: personal utility of a genetic diagnosis for families</article-title><source>Epilepsia Open</source><volume>6</volume><year>2021</year><fpage>149</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">33681658</pub-id>
</element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sbref300"><person-group person-group-type="author"><name><surname>Bowman-Smart</surname><given-names>H</given-names></name><name><surname>Vears</surname><given-names>DF</given-names></name><name><surname>Brett</surname><given-names>GR</given-names></name><name><surname>Martyn</surname><given-names>M</given-names></name><name><surname>Stark</surname><given-names>Z</given-names></name><name><surname>Gyngell</surname><given-names>C</given-names></name></person-group><article-title>&#x0201c;Diagnostic shock&#x0201d;: the impact of results from ultrarapid genomic sequencing of critically unwell children on aspects of family functioning</article-title><source>Eur J Hum Genet</source><volume>30</volume><year>2022</year><fpage>1036</fpage><lpage>1043</lpage><pub-id pub-id-type="pmid">35831422</pub-id>
</element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sbref310"><person-group person-group-type="author"><name><surname>Heyne</surname><given-names>HO</given-names></name><name><surname>Singh</surname><given-names>T</given-names></name><name><surname>Stamberger</surname><given-names>H</given-names></name><etal/></person-group><article-title>De novo variants in neurodevelopmental disorders with epilepsy</article-title><source>Nat Genet</source><volume>50</volume><year>2018</year><fpage>1048</fpage><lpage>1053</lpage><pub-id pub-id-type="pmid">29942082</pub-id>
</element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sbref320"><person-group person-group-type="author"><name><surname>Costain</surname><given-names>G</given-names></name><name><surname>Cordeiro</surname><given-names>D</given-names></name><name><surname>Matviychuk</surname><given-names>D</given-names></name><name><surname>Mercimek-Andrews</surname><given-names>S</given-names></name></person-group><article-title>Clinical application of targeted next-generation sequencing panels and whole exome sequencing in childhood epilepsy</article-title><source>Neuroscience</source><volume>418</volume><year>2019</year><fpage>291</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">31487502</pub-id>
</element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sbref330"><person-group person-group-type="author"><name><surname>Gorzynski</surname><given-names>JE</given-names></name><name><surname>Goenka</surname><given-names>SD</given-names></name><name><surname>Shafin</surname><given-names>K</given-names></name><etal/></person-group><article-title>Ultrarapid nanopore genome sequencing in a critical care setting</article-title><source>N Engl J Med</source><volume>386</volume><year>2022</year><fpage>700</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">35020984</pub-id>
</element-citation></ref></ref-list><sec id="sec1" sec-type="supplementary-material"><title>Supplementary Material</title><p id="para520">
<supplementary-material content-type="local-data" id="ecomp10"><caption><title>Supplementary appendix</title></caption><media xlink:href="mmc1.pdf"/></supplementary-material>
</p></sec><ack id="ceack10"><sec><title>Acknowledgments</title><p>We thank the patients and their families who participated in this study. The Boston Children's Hospital (BCH) site is supported by the BCH Children's Rare Disease Cohorts Initiative and the One8 Foundation. AMD is supported by the National Institute of Child Health and Human Development (T32 HD 098061) and the American Academy of Pediatrics (Marshall Klaus Neonatal-Perinatal Research Award). BRS, RV, and APo are supported by the One8 Foundation. BRS, JK, BTO, and APo are supported by the Robinson Family Initiative for Transformational Research. The Toronto authors acknowledge support from the following funders: Canadian Institutes of Health Research (PJT186240); Epilepsy Canada (New Investigator Award to GC); Feiga Bresver Academic Foundation; Ontario Brain Institute (this research was conducted with the support of the Ontario Brain Institute, an independent non-profit corporation, funded partially by the Ontario Government. The opinions, results, and conclusions are those of the authors and no endorsement by the Ontario Brain Institute is intended or should be inferred); and University of Toronto McLaughlin Centre. RZH is supported by a Canada Research Chair in Genomics and Health Policy (CRC-2021-00284). Funding for the Melbourne Children's Campus site was provided by The Royal Children's Hospital Foundation and seed funding from the MCRI. The MCRI is supported by the Victorian Government's Operational Infrastructure Support Program. KBH is supported by a Melbourne Children's Clinician Scientist Fellowship. IES and KBH are supported by the National Health and Medical Research Council (NHMRC) Centre for Research Excellence Grant (GNT2006841). IES has a NHMRC Synergy Grant (GNT2010562) and Senior Investigator Grant (GNT1172897), and is supported by the Australia Medical Research Future Fund and Australian Epilepsy Research Fund. AM is supported by the MRC (MR/T007087/1), Great Ormond Street Hospital (GOSH) Charity (VS0122), Rosetrees Trust, and Wellcome Trust TIN Scheme. SEN, ES, LSC, JHC, and AM are supported by the GOSH National Institute for Health and Care Research (NIHR) Biomedical Research Centre (BRC). LSC is supported by the GOSH Childrens Charity and received discounted consumables from Illumina. JH is supported by an Action Medical Research and British Paediatric Neurology Association Research Training Fellowship (GN2945). This work is partly funded by the NIHR GOSH BRC. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health.</p></sec></ack><ack><title>Gene-STEPS Study Group</title><p>Christelle Achkar, Anoushka Alwis, Danielle Andrade, Patrick Asselin, Sanjay Bhate, Christina Briscoe Abath, Madeline Campbell, Lara Carr, Lucinda Carr, Angela Chan, Eunice K Chan, Beth Cole, Lisette Curnow, Sarah R Curnow, Gabriel Dabscheck, Sameer Dal, Krishna Das, Michelle de Silva, Nivedita Desai, Stephanie Donatelli, Elizabeth J Donner, James J Dowling, Amr El Shahed, Christin Eltze, Noelle Enright, Nicola Fearn, Jillian Fitzgerald, Jeremy L Freeman, Julia Frueh, Dustin Gable, Vijeya Ganesan, Susan Greaves, Yael Hacohen, Jane Hassell, Michael Hayman, Jody Heffernan, Rachel G Hirschberger, Maximilian A Horlbeck, Terrie Inder, Kathryn Irving, Manny Jacobs, Trupti Jadhav, Divya Jayaraman, Marios Kaliakatsos, Rachel Kerr, Fakhra Khalid, Andrew J Kornberg, Christine Koroshegyi, Lynette Lau, Merari J Lavander-Ferreira, Richard J Leventer, Emma Macdonald-Laurs, Mark T Mackay, Rebecca MacRae, Eva Mamak, Candice Marti, Roberto Mendoza-Londono, Steven P Miller, Alisa Mo, Chariton Moschopoulos, Amy Muggeridge, Archana Patel, Rebecca Pinsky, Chien Yen Poh, Heather Pomella, Suresh Pujar, Melinda Randall, Hanna Richardson, Robert Robinson, Victoria Rodriguez-Casero, Penny Snell, Martin Somerville, Robert C Stowe, Anna Szuto, Stephanie Tung, Rosanna Weksberg, Diane Wilson, Ian R Woodcock, Eppie M Yiu, Michael Yoong, Ryan K C Yuen, Christoper J Yuskaitis.</p></ack><ack><title>IPCHiP Executive Committee</title><p>Nancy C Andrews, Alan H Beggs, John Christodoulou, J Helen Cross, Christian R Marshall, Kathryn N North, Stephen W Scherer, Neil J Sebire, Piotr Sliz, Rosalind L Smyth, David A Williams.</p></ack><ack><title>Contributors</title><p>AMD, BRS, VC, GC, APo, KBH, AM, and members of the IPCHiP Executive Committee conceptualised the study. AMD, SM, BRS, FB, SB, TK, JH, JK, NSYL, LM, BTO, APa, RV, PJ, IES, VC, APo, KBH, AM, and members of the Gene-STEPS Study Group did the patient recruitment. AMD, SL, GC, APo, KBH, and AM curated the data. AMD did the formal analysis. AMD, SM, BRS, NJC, MC, EJH, JK, BTO, BP, ES, RV, KW, SL, CRM, NS, ZS, SMW, LSC, IES, VC, GC, APo, KBH, and AM did the investigation. AMD, BRS, SEN, GR, RZH, SL, SR, NS, ZS, SMW, LSC, JHC, VC, GC, APo, KBH, and AM did the methodology. AMD, SM, BRS, JC, VC, GC, APo, KBH, AM, and members of the Gene-STEPS Study Group did the project administration. GC, APo, KBH, and AM supervised the study. GC, APo, KBH, and AM validated the data. AMD did the figures and tables. AMD, SM, APo, KBH, and AM wrote the original draft. All authors reviewed and edited the manuscript, as well as had full access to all the data in the study and accept responsibility to submit for publication.</p></ack></back></article>